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CHAPTER 1 “DENDRIMER−BASED NANODEVICES”
1.1 Dendrimers in Nanomedicine: The Rationale
Due to their unique properties dendrimers have exceptional potential for the application in
the emerging field of nanomedicine. The goal of nanomedicine is to control and manipulate
biomacromolecular constructs and supramolecular assemblies such as proteins, DNA/RNA,
viruses, cellular lipid bilayers, cellular receptor sites and antibody variable regions that are
critical to living cells in order to improve the quality of human health. The nanotherapeutics and
diagnostic devices will allow a deeper understanding of human life and illnesses such as cancer,
cardiovascular disease, genetic disorders, and trauma.1 Detection of a disease in its earliest stage
is the ultimate goal.
Dendrimers are polymers having highly branched structures and globular shapes with the
nanosize ranging from 2 to 10 nm. Due to their exceptional structural properties such as
monodispersity, controllable size and structure, modifiable surface functionalities, and
multivalency they have become prominent synthetic macromolecules in the field of biomedical
science. Dendrimers are widely utilized as drug delivery systems, antiviral agents and magnetic
resonance imaging contrast agents.2-7 In the past decades dendrimers have been investigated as
novel diagnostic nanodevices.8,9 They have been utilized in dip-pen nanolithography,10 DNA and
protein arrays,11,12 nanocatalyst-based electro-chemical immunosensor,13 biosensor-based on
dendrimer encapsulated Pt nanoparticles14 and regenerable affinity biosensing surfaces.15
Research in antibody-based diagnostics has been focused on improving the specificity and
sensitivity of immunoassay techniques.

The most important steps in the development of

immunosensors are the immobilization of antibodies onto a substrate at high density with
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uniform distribution, retaining their specific antigen-binding activities, maintaining accessibility
to the antigens,16 and minimizing nonspecific adsorptions of extraneous cellular proteins onto the
modified surfaces, which can reduce the sensitivity during detection steps. Based on their
properties, dendrimers could play an essential role in each of these steps. Dendrimers can form
stable, dense, well-organized, and close-packed arrays on substrate surfaces and they have ability
to incorporate multiple branch ends available for conjugation reactions.8 Recently Kannan’s
group has reported a dendrimer based ELISA assay for IL-6 and IL-1β cytokines capture that are
found in infected intraamniotic fluid.17 The dendrimer modified plate provides assays with
significantly enhanced sensitivity, lower nonspecific adsorption, and

significantly higher

detection limits compared to traditional ELISA.
Controlled delivery of drugs can sustain blood level of the drug over a long period of
time, decrease side effects, and lead the drug through the body without degradation, increase
drug solubility, and decrease dose. The functional surface groups on dendrimers can affect their
physicochemical properties. It is known that these functional groups make dendrimers very
hydrophilic and highly water soluble.18 Drug molecules can be either encapsulated, complexed,
or covalently attached to the dendrimers through their functional groups.19,20 The most common
covalently linkage of the drugs to surface functional groups of dendrimers can be achieved by a
coupling reaction through the ester or amide bonds. If the drug does not have a reactive group, a
spacer or linker molecules are very often used to provide the drug with reactive group, which is
required for coupling reaction with dendrimer. These ester or amide bonds, can be cleaved either
hydrolytically or enzymatically.21 The drug release due to hydrolysis will be governed by the pH
of the media and ester bonds are more liable towards the hydrolysis compared to amide bonds.22
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The study has showed that ester linked conjugates in human plasma can be hydrolyzed by
esterase enzymes, while amide bonds are relatively stable.23,24 Disulfide bonds have also been
demonstrated to be cleaved in the presence of intracellular glutathione (GSH).25 Targeting
ligands can be linked to the functional groups of dendrimers too, and used for targeted drug
delivery.20
The key issues in the design of dendrimer-drug nanodevices include improving drug
payload, overcoming cytotoxicity especially in the case of cationic dendrimers, understanding
the mechanism and dynamics of intracellular transport, and engineering of the drug release at the
appropriate tissue. This can be achieved by optimizing biodistrubution, passive targeting –
mediated via EPR (enhanced permeability retention) effect involving organ-specific targeting,
and active targeting – receptor-mediated cell-specific targeting involving receptor-specific
targeting groups.1,22 Cellular uptake of dendrimers is affected by their size, type and the charge
of surface groups.26,27 Although there has been a significant success of attaching a multiple drug
molecules on dendrimers, optimal release of drugs is still a challenge. Presence or absence of
linker can greatly affect the drug release from dendrimers.21 High stability of the conjugate or
release of the drug before reaching its target will make the dendrimer-drug-delivery system
ineffective.
1.2 Introduction to Dendrimers
Dendrimers are well-defined polymeric macromolecules having nanometer size and
unique properties. The structure of dendrimers consists of a repetitive sequence of monomers,
called branching units (dendrons). These units are growing from a core in a radial iterative
fashion giving rise to higher generations (Figure 1). Beside the branching units, dendrimers
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always have core units, and surface groups located at their peripheries.28 Due to controlled step
by step synthesis dendrimers are nearly monodisperse architectures (polydispersity indexes
close to 1),29 in contrast to traditional polymers. One of the most attracting aspects reletad to
dendrimers is that it is relatively easily to control their size, composition, and physicochemical
properties in a very precise manner.

Figure 1. Schematic representation of generation four hydroxyl PAMAM dendrimer.

This type of molecules were first time synthesized by Vögtle in 1978 and called
cascade.30 The synthesis involves two steps; first step is an exhaustive Michael-type addition of
acrylonitrile to an amine, and second step is reduction of nitrile groups to primary amines. These
steps could be theoretically repeated to give highly branched macromolecules, but there are
difficulties due to loss of substrate catalytic activity and poor yields. In early 1980s Denkewalter
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and co-workers patented the synthesis of polylysine dendrimers.31 Then in 1985, similar type of
molecules were synthesized independently by Newkome and Tomalia groups.32,33 Newkome
named his molecules as arbosols, while Tomalia dendrimers, based on two greek words,
‘dendros’ meaning tree and ‘meros’ meaning part.
1.3 Synthesis of Dendrimers
There are two approaches for dendrimer synthesis. First approach is called divergent
method that was developed by Tomalia. Tomalia synthesized poly(amidoamine) (PAMAM)
dendrimers by this method, in which the growth of dendrimer starts from a core as the root and
goes outward building up generation by generation. The second approach, developed by Hawker
and Fréchet, is convergent method, which proceeds from the dendron surface inward to a
reactive focal point at the root.
1.3.1 Divergent Method
The name of divergent method originates from the way how dendrimers grow starting
from the core and going outwards, i.e. diverging into space (Figure 2). The synthesis consists of
two steps: the core is reacted with two or more moles of reagent containing at least two protected
branching sites, followed by removal of the protecting groups. The subsequent deprotected
reactive sites lead to the zero generation dendrimers. This process can be repeated until the
dendrimer with desired size and nuber of terminal groups is obtained. Usually ethylene diamine,
ammonia, or cystamine may be used as cores.34 relatively large dendrimers can be prepared using
this method. However, the isolation and characterization can be hard due to incomplete growth
steps and side reactions.
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Figure 2. Dendrimer synthesis by divergent growth method [Adopted from Ref. 28]

1.3.2 Convergent Method
In response to the disadvantages of divergent method convergent method was developed
by Hawker and Fréchet in 1990 (Figure 3).35 The synthesis involves two steps: the first is a
reiterative coupling of protected/deprotected branching units to obtain a focal point
functionalized dendron and the second is the reaction of several dendrons leading to formation of
dendrimer. Basically, the convergent growth starts at the surface of the dendrimer and proceeds
inwards by progressively linking surface units with other monomers. When the growing blocks,
called dendrons, are large enough, several of them are attached to an appropriate core to give a
complete dendritic structure. Compared to divergent method the convergent method requires
only two simultaneous reactions for any-adding step, it has lower number of side reactions and
purification of dendrimers is simpler.

Figure 3. Dendrimer synthesis by convergent growth method [Adopted from Ref. 28]
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1.4 Properties of Dendrimers
Dendrimers have crucial properties required for fabrication of the synthetic nanostructures
with size, shape, surface chemistry similar to nanobiological constracts. They are nearly
monodisperse, nanoscale size, well-defined molecular structures. Their size is similar to globular
proteins. Generation 4 PAMAM dendrimer has size comparable to cytochrome c (4 nm),
generation 5 PAMAM dendrimer has size comparable to hemoglobin (5 nm), and so on. Based
on their systematic, dimensional length scaling, narrow size distribution, and biomimetic
properties dendrimers are like ‘artificial proteins’.36 On the contrary to proteins, dendrimers are
known to be robust, covalently fixed, three-dimensional structures possessing both solvent-filled
interior hollowness and defined surface functionality.
Dendrimers are multivalent ligands due to presence of high number of reactive terminal
groups. Dendritic scaffolds, compared to the other multivalent ligands such as polymers,
proteins, and liposomes, exhibit advantageous controllable synthesis pathway. They have the
ability of linking different chemical moieties on the surface, and in the interior. Dendrimer
surface may be functionally designed to enhance or reduce trans-cellular, epithelial or vascular
biopermeability. They also have a void space within the structure of the scaffold suitable for
encapsulation of small-molecule drugs, metals (e.g. gold, silver) or signalling groups. These
features make dendrimers ideal drug carriers with high drug payload capacities.37 Complexation
of the drug to the dendrimers can lead to enhanced permeation and retention (EPR) of the drug in
the targeted sites.1
The properties of dendrimrs are tailored by the functional groups on their surface. They can
be water-soluble when their end-groups are hydrophilic such as hydroxyl, amino, and carboxyl

8

groups as seen in PAMAM dendrimers. Dendrimer conformations are determined by dendrimer
growth, the nature of building blocks, end-group functionalities, and the external environment.29
Hydrogen bonding of terminal groups makes outer shell of dendrimers more rigid. Conforamtion
of dendrimers stricktly depends on pH. At low pH (~3), all primary amine groups of PAMAM
dendrimers are protonated leading to an extended conformation due to electrostatic repulsion
between the positively charged NH3+ groups. At neutral pH back folding occurs which is due to
the hydrogen bonding between the uncharged tertiary amines in the interior and the positively
charged surface amines. At basic pH the dendrimer is completely neutralized and repulsive
interactions between the wedges and end-groups reach a minimum leading to a conformation
with a higher degree of back folding so dendrimer acquires a more spherical (globular) structure.
The conformation of dendrimers is also affected by the polarity of the solvent as well as the ionic
strength (high concentration of salts).28
In order to use dendrimers for drug design or as drug delivery devices in vivo, dendrimers
have to be non-toxic, non-immunogenic (except for vaccines), and able to cross biobarriers
(biopermeable) such as, the intestines, the blood–tissue barriers, cell membranes, and so on.
They also have to be capable of staying in circulation for the time needed to target specific
organs and exhibit clinical effects. The cytotoxicity of dendrimers is related to their size and
surface groups which are directly interacting to cells’ membrane. It has been reported that
cationic dendrimers show heamolitic and cytotoxic effect at even relatively low concentration,
while anionic and hydroxyl terminated dendrimers are not toxic. The studies showed that aminoterminated PAMAM dendrimers are weakly immunogenic, which can be eliminated by
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pegylation with polyethylene glycol (PEG) chains. It also extends dendrimers lifetime in the
blood stream compared to unmodified dendrimers.38
1.5 PAMAM Dendrimers
Polyamidoamine (PAMAM) dendrimers were synthesized by Tomalia.33 They are known
to be first commercialized dendrimers family, which are the most extensively characterized and
widely used. PAMAM dendrimers have ethylene diamine (EDA) core and an amidoamine repeat
branching structure. They are synthesized via Michael addition of amino groups of EDA with
methyl acrylate, followed by amidation of the resulting esters with EDA, and generation 0 is
formed (Figure 4). A repetition of these two synthetic steps adds another layer of branching units
and produces next generation. The size of dendrimer grows linearly in diameter as a function of
added generations, approximately 1 nm per generation (Table 1). Each new generation also
doubles the number of terminal groups and approximately doubles the molecular weight of the
previous generation. Figure 4 shows the synthesis of amine (NH2) terminated PAMAM
dendrimers that are cationic; however there are also neutral hydroxyl (OH) and anionic carboxyl
(COOH) terminated PAMAM dendrimers. Due to half completion of the monomer addition the
carboxyl terminated dendrimers are called half generations. These active terminal groups make
dendrimers multivalent and they can be used to covalently attach several drug molecules,
targeting groups, and other agent to the periphery of dendrimers in a well-defined manner. To
avoid sterical hindrance and to provide drug with reactive group, a variety of spacer molecules
can be linked to the drug and as such used for conjugation reaction with dendrimers. The
presence of hydrophilic terminal groups makes dendrimers highly water soluble. The solubility
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increases with the generation number; the higher generation, the higher number of terminal
groups, leads to increased surface charge and polarity.

Figure 4. Synthesis of PAMAM dendrimer by Tomalia et al33

Table 1. Physicochemical characteristics of amine terminated PAMAM dendrimers
Generation
0
1
2
3
4
5
6
7
8
9
10

Number of surface
groups
4
8
16
32
64
128
256
512
1024
2048
4096

Molecular weight

Diameter (nm)

517
1,430
3,256
6,909
14,215
28,826
58,048
116,493
233,383
467,162
934,720

1.5
2.2
2.9
3.6
4.5
5.4
6.7
8.1
9.7
11.4
13.5
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1.6 Research Objectives
Over the past several decades, a great number of dendrimer structures with various
chemical compositions have been developed and investigated for a variety of applications in
physics, chemistry, biology, and medicine. Among them, poly(amidoamine) (PAMAM)
dendrimers are the most extensively characterized and widely used. Even though many different
surface end functionalities are available on these dendrimers, -NH2, -OH, and -COOH end
groups are the most commonly studied. Of these, the hydroxyl-terminated ethylenediamine core
generation 4 poly(amidoamine) dendrimers (G4-OH PAMAM) that are highly biocompatible,
and have low protein interactions are explored here as vehicles for targeted intracellular drug
delivery. The overall scientific goal of this research is to tailor the G4-OH PAMAM dendrimer
surface, linking chemistry, and other physicochemical properties for enabling covalent linking
with drugs, imaging agents and antibodies, to impact the improved functionality in the resultant
nanodevices. Two specific goals are pursued: (1) development of G4-OH PAMAM dendrimer –
drug nanodevices, and (2) development of G4-OH PAMAM dendrimer-based multipurpose
novel diagnostic platforms. As mentioned dendrimers have multiple terminal functional groups
available for further conjugation between dendrimer functionalities and guest molecules. The
most common covalent linkages of the guest molecules to surface functional groups of
dendrimers are ester or amide that are usually obtained by coupling reactions. Recently our
group has been used disulfide bond to link the drug molecules to dendrimers.25 In the case of the
development of dendrimer-drug nanodevices choosing the right linkage and/or putting the proper
spacer between the dendrimer and drug molecules the drug payload can be increased, the
cytotoxicity especially in the case of cationic dendrimers will be avoided, and the drug will
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release at the appropriate tissue. The development of dendrimer-based diagnostic nanodevices
includes dendrimer-linked antibody assays. The design involves various linking chemistries
between solid support and dendrimer, and between dendrimer and antibody such as amide,
sulfide, and hydrazone bonds. Introducing the dendrimer as a spacer between antibody and solid
support reduces non-specific interactions between immobilized antibody and analyte which will
improve the detection limits.
In this thesis four chapters are discussed. In Chapter 1 an overview of dendrimers
evolution and their role in nanomedicine is summarized. The synthesis, characterization, and in
vitro study of dendrimer-Erythromycin (D-EM) nanodevice for sustained treatment of orthopedic
inflammation are described in Chapter 2. In Chapter 3 the G4-OH PAMAM dendrimer is used to
develop an immunoassay for detection of TNF-α cytokine. Chapter 4 describes the synthesis,
characterization, and in vitro studies of dendrimer-allopregnanolone isomer and dendrimerallopregnanolone nanodevices for traumatin brain injury (TBI) treatment.
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CHAPTER 2 “SYNTHESIS, CHARACTERIZATION, DRUG RELEASE PROFILE,
AND

IN

VITRO

EFFICACY

OF

PAMAM

DENDRIMER-ERYTHROMYCIN

NANODEVICES”
2.1 Abstract
Erythromycin (EM), an antibiotic that has been used for infectious diseases, is now
gaining attention because of its novel anti-inflammatory effects. A dendrimer-EM nanodevice is
explored for sustained treatment of orthopedic inflammation. To sustain pharmacological
activity, EM has been conjugated to poly(amidoamine) dendrimer (PAMAM) through an ester
bond. Hydroxyl-terminated poly(amidoamine) dendrimer (G4-OH) was reacted to a protected
amine linker followed by deprotection to obtain a bifunctional dendrimer that contains 10-15 %
amine groups. EM was modified to EM-glutarate then conjugated to the bifunctional dendrimer
through an amide bond. The cytotoxicity and activity of this EM-dendrimer conjugate was
evaluated on RAW 264.7 cells in vitro by lactate dehydrogenase (LDH) assay and nitric oxide
(NO) assay, respectively. From LDH assay dendrimer-EM conjugate and free EM were found to
be non-cytotoxic within the dose range 0.1-1 µg/mL after 48 hours. Dendrimer-EM conjugate
showed significant nitrite inhibition activity, reducing the nitrite levels by 42 % as compared to
those in untreated cells. Dendrimer-EM conjugate has better efficacy than free EM for dose
concentration of 1-10 µg/mL. The improvement in the in vitro efficacy of EM by dendrimer
conjugation was the strongest within the dosage range of (5-10) µg/mL. The zone of inhibition of
dendrimer-EM conjugate on bacterial growth at different concentrations showed similar activity
compared to free EM treatment with equivalent dose. Furthermore, free dendrimer did not show
any effect of bacterial inhibition at the concentration up to 0.2 mg/mL.
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2.2 Introduction
Dendrimers are polymers with highly branched structures and globular shapes with the
size range 2-10 nm. Due to their properties such as monodispersity, controllable size and
structure, tailorable surface functionality, and multivalency, they are extensively investigated for
various biomedical applications2,36 such as drug delivery systems,5-7 antiviral agents, and as
magnetic resonance imaging contrast agents.3,4 PAMAM dendrimers have also been studied in
isolation as topical antibacterial agents to treat intrauterine infections.39 In the past decades
dendrimers have been investigated as novel diagnostic nanodevices.8,9 Recently our group has
reported a dendrimer based ELISA assay for IL-6 cytokine detection that is found in infected
intraamniotic fluid.17
Controlled delivery of drugs can sustain blood level of a drug over a longer period of
time, limit side effects, and lead the drug through the body without degradation, increase drug
solubility, and decrease dose frequency. It is well known that the functional surface groups on
dendrimers can affect their physicochemical properties, making them hydrophilic. Conjugation
of poorly water-soluble drugs to PAMAM dendrimers increases the bioavailability as well as
drug solubility and decreases the dose frequency.18,40,41 Drug molecules can either be
encapsulated and complexed, or covalently attached to the dendrimers through their functional
groups.19,20 The most common covalent linkage of the drugs to the surface functional groups of
dendrimers can be achieved through the ester or amide bond which can be cleaved hydrolytically
or enzymatically.21 In the recent past disulfide bonds have also been demonstrated to be cleaved
in presence of intracellular glutathione (GSH).25 Ligand can be attached to the dendrimer to
increase the accumulation of drug at the targeted site.20 Neutral PAMAM dendrimers with no
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targeting ligands have been shown to have an intrinsic ability to localize in cells associated with
neuroinflammation in a rabbit model of cerebral palsy.42 The key issues in the design of
dendrimer-drug conjugates include improving drug payload; overcoming cytotoxicity especially
in the case of cationic dendrimers; understanding the mechanism and dynamics of intracellular
transport; and engineering the drug release at the appropriate tissue. The cellular uptake of
dendrimer is also affected by their size, construct, surface functional groups and their charge.26,43
Premature or lack of drug release from the dendrimer-drug conjugate before the appropriate time
can decrease the in vivo effectiveness.
Total joint replacement (TJR) has been very successful in restoring function and mobility
to millions of patients worldwide since its advent more than thirty years ago. With improvements
in prophylaxis against infection, the fatigue strength of the components, and skeletal fixation,
wear debris- induced periprosthetic membrane inflammation has become the primary limitation
to TJR longevity.44 There is currently no cure for aseptic loosening (AL) patients with osteolysis
except revision surgery, primarily due to a lack of safe or effective drug candidate(s).45 A recent
approach to limiting osteolysis has focused on reducing periprosthetic inflammation and
enhancing periprosthetic bone quality.45-47 Erythromycin (EM) has been used for infectious
disease for over 50 years.48 For the last decade, EM has attracted a great deal of attention
because of its novel anti-inflammatory effects far beyond antibiotics.49,50 EM demonstrates a
unique

“phagocyte

targeted

delivery”

property,

favorable

concentrating

in

monocyte/macrophages.51-54 There are accumulating evidence,55 that EM exerts its antiinflammatory effects through targeting to NF-κB signaling.56-58 Data from previous studies
showed that EM inhibits wear debris-induced inflammation and osteolysis (both in vitro and in
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vivo),55,59-62 suggesting that EM represents an appropriate drug candidate to prevent or treat
periprosthetic membrane inflammation. However, delivering adequate levels of EM to the site of
periprosthetic inflammation, without undesirable systemic side effects, presents a considerable
challenge. The goal of this work is to develop and validate intravenously dendrimer-EM delivery
nanodevices that can target the periprosthetic tissue and reduce local inflammation in a sustained
manner.
In this Chapter the synthesis and characterization of hydroxyl terminated generation four
PAMAM dendrimer-Erythromycin conjugate (dendrimer-EM) and its in vitro activity and
cytotoxicity is described. First, PAMAM G4-OH was partially functionalized with amine groups
using amino-valeric acid as linker and then conjugated to EM-2′-glutarate via EM-glutarate-Nsuccinimidyl ester intermediate. The cell toxicity was determined by measuring the release of
lactate dehydrogenase (LDH) from dead or dying cells into the culture medium using a
Cytotoxity Detection Kit. A zone of inhibition study was performed using the modified KirbyBauer Method to determine the levels of Staphylococcus aureus (S. aureus) activity inhibited by
dendrimer-EM conjugate release in the sample eluents. The effect of dendrimer-EM conjugate
on LPS-induced nitrite production in RAW 264.7 cells was demonstrated. The cell studies were
done at the Biomedical Engineering by our collaborator, Dr. Ren’s lab.
2.3 Materials and Methods
2.3.1 Materials
Generation four hydroxyl terminated PAMAM dendrimer (G4-OH) with ethylendiamine
core and 64 surface groups (MW 14,279) in methanol solution was purchased from Dendritech
Inc. (Midland, MI, USA). N-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDC), 4-
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(dimethylamino) pyridine (DMAP), glutaric anhydride, 5-(tert-butoxycarbonyl-amino)valeric
acid, N,N-dimethylacetamide (DMA), diphenyl chlorophosphate and lipopolysaccharide (LPS,
Escherichia coli O55:B5) were purchased from Sigma-Aldrich Chemical Company (St. Louis,
USA). Triethylamine (TEA) and N-hydroxysuccinimide (NHS) were purchased from Thermo
Scientific. Trifluoroacetic acid (TFA), dimethylformamide (DMF), and dimethyl sulfoxide
(DMSO) were purchased from EMD. All anhydrous solvents DMSO, DMF, acetonitrile (ACN),
and dichloromethane (DCM) were purchased from Acros Organics, USA. Fluorescein
isothiocyanate (FITC) was obtained from Alfa Aesar, MA, USA. All other solvents and
chemicals used were purchased from Fisher Scientific. Regenerated cellulose (RC) dialysis
membrane with molecular weight cut-off of 1000 Da was obtained from Spectrum Laboratories.
DMEM medium was purchased from Gibco-BRL Life Technologies, USA. FBS (fetal bovine
serum) was purchased from HyClone Laboratories (Utah, USA).
All reactions were carried out under nitrogen conditions. The anhydrous solvents and
other reagents that are commercially available were directly used without further purification.
Thin layer chromatography (TLC) was performed on silica gel GF254 plates (Watmann) and the
spots were visualized with UV light and 2% H2SO4 in EtOH.
2.3.2 Characterization
NMR spectra were recorded on a Varian INOVA 400 spectrometer using commercially
available deuterated solvents. Proton chemical shifts are reported in ppm (δ) and
tetramethylsilane (TMS) used for internal standard. Coupling constants (J) are reported in hertz
(Hz). ESI mass spectra were recorded on Waters Micromass ZQ spectrometer. Matrix-assisted
laser desorption ionization-time of flight (MALDI-TOF) mass spectra were recorded on a Bruker
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Ultraflex system equipped with a pulsed nitrogen laser (337 nm), operating in positive ion
reflector mode, using 19 kV acceleration voltage and a matrix of 2,5-dihydroxybenzoic acid.
Cytochrome C (MW 12,361 g/mol), and Apomyoglobin (MW 16,952 g/mol) were used as
external standards. A dendrimer solution was prepared by dissolving 2 mg of dendrimer in 1 mL
of DMSO. The matrix solution was prepared by dissolving 20 mg of matrix in 1 mL of the 1:1
mixture of deionized water and acetonitrile (0.1% TFA). Analytical samples were prepared by
mixing 10 µL of dendrimer solution with 100 µL of matrix solution, followed by deposition of 1
µL of sample mixture onto a 384-well aluminum plate. This mixture was allowed to air dry at
room temperature.
2.3.3 HPLC Characterization
High performance liquid chromatography (HPLC) characterization was carried out using
Waters HPLC instrument equipped with dual pumps, an auto-sampler and dual UV detector
interfaced to Breeze software. The HPLC chromatogram was monitored at 210 and 238 nm
simultaneously using the dual UV absorbance detector. H2O:ACN (0.14 % TFA) was used as
mobile phase. Both phases were freshly prepared, filtered, and degassed prior to use.
Symmetry300 C18 reverse-phase column (5 µm particle size, 25 cm × 4.6 mm length × I.D.)
equipped with a Supelguard Cartridges (5 µm particle size, 2.0 cm ×3.9 mm length × I.D.) was
used for characterization of the conjugates. HPLC analysis was done using 90:10 to 30:70
(H2O:ACN) gradient flow in 30 minutes with flow rate of 1 mL/min.
2.3.4 Release Study Protocol
The release studies were performed in 0.1M PBS buffer solution (pH = 7.4). The
conjugate was added into 3 mL preheated buffer solutions in triplicates. All the release solutions
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containing 2.5 mg/mL dendrimer drug conjugate were stirred continuously and maintained at
37ºC. At appropriate time intervals samples were withdrawn and immediately analyzed by HPLC
to determine the EM concentrations.
2.3.5 Dynamic Light Scattering and ζ-Potential
The particle size and ζ-potential of G4-OH and dendrimer conjugates were determined by
dynamic light scattering (DLS) using a Malvern Instruments Zetasizer Nano ZEN3600
instrument (Westborough, MA). The samples were dissolved in DI water (18.2 Ω) and filtered
using AccuSpin Micro 17/17R ultracentrifuge (Fisher Scientific). DLS measurements were
performed at a 173° scattering angle at 25°C.
2.3.6 RAW 264.7 Cell Culture Stimulation, and Dendrimer Treatment
Murine RAW 264.7 macrophage cell line was obtained from the American Type Culture
Collection (ATCC, Rockville, MD). RAW 264.7 cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco BRL, MD) containing 10% fetal bovine serum (FBS) and
antibiotics (100 units/mL of penicillin-G and 100 µg/mL of streptomycin) at 37°C in a
humidified incubator with 5% CO2. RAW 264.7 cells were plated at a density of 1 × 105
cells/well, in 96-well plates in the presence of LPS (1 µg/mL) with or without dendrimer-EM
conjugate at different concentrations for 48 hours.
2.3.7 Cell Toxicity Assay
Cell toxicity was determined by measuring the release of lactate dehydrogenase (LDH)
from dead or dying cells into the culture medium using a Cytotoxity Detection Kit (Roche
Diagnostics BmbH) following the manufacturer’s instruction. 48 hours after treatment of
dendrimer-EM conjugates at different concentrations, the conditioned media were collected and
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used for the measurement of LDH activity. Briefly, 100 µL of culture medium was added into a
plate of 96 wells, mixed with 100 µL working solution and incubated at room temperature for 30
minutes in the dark. Then, the plate was read under the UVmax colorimeter (Molecular Devices)
at OD 490 nm. Blank culture medium was used as a blank control and the total cell lysate was
used as a positive control as well. LDH activity was expressed as absorbance (OD) per mg
protein.
2.3.8 Detection of Nitrite Production
RAW 264.7 cells (passage 10) (5 × 105 cells per well) were cultured in triplicate in 24well plates and stimulated with 1 µg/mL LPS (positive control), and 1 µg/mL LPS [+EM,
+dendrimer, or +D-EM] for 48 hours. The concentrations of free EM were 0.1, 1.0, 5.0, and 10.0
µg. They corresponded to the concentration of EM in the dendrimer-EM conjugate. The
production of nitric oxide (NO) was determined by assaying culture supernatant for nitrite
(NO2−), a stable reaction product of NO. In brief, 100 µL of culture supernatant was mixed with
an equal volume of Griess reagent (Cayman) (1% sulfanilamide and 0.1% N-[naphthyl]
ethylenediamine dihydrochloride in 2.5% H3PO4) at room temperature for 10 min. Absorbance
was measured at 540 nm in a microplate reader. Nitrite concentration was calculated from a
NaNO2 standard curve.
2.3.9 Antibacterial Assay
Staphylococcus aureus (S. Aureus) strain was used for the present study. A zone of
inhibition study was performed using the modified Kirby-Bauer Method to determine the levels
of S. aureus activity inhibited by dendrimer-EM conjugate release in the sample eluents. Growth
of the organism and diffusion of the EM commence simultaneously resulting in a circular zone
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of inhibition in which the amount of dendrimer-EM conjugate exceeds inhibitory concentrations.
The diameter of the inhibition zone reflects the function of the dendrimer-EM conjugate amount
in the eluents. A disk paper soaked with the dendrimer-EM/PBS solution with known
concentration was put into a bacterial agar plate, inoculated with the bacteria strain of S. aureus,
for the zone of inhibition test. This strain of S. aureus is the main bacteria causing bone
infection. The bacteria plates were incubated for 24 hours, and then the diameter of the zone of
growth inhibition around each disk to the nearest whole mm were measured. The results were
expressed as the size of zone of inhibition. All the tests were performed in triplicate, and
repeated two times.
2.3.10 Preparation of Bifunctional PAMAM Dendrimer (G4-OH-Link-NH2, 2)
The reaction scheme for the preparation of the conjugate 2 is outlined in Figure 5. The 5(Boc-amino)valeric acid (168.9 mg, 0.7774 mmole) was dissolved in DMSO (10 mL). EDC
(447 mg, 2.33 mmole) and DMAP (10.0 mg, 0.0818 mmole) each dissolved in DMSO (5 mL)
were added under nitrogen atmosphere. The mixture was allowed to stir for 1 hour at room
temperature and PAMAM G4-OH (370.0 mg, 0.0259 mmole) dissolved in DMSO (5 mL) was
added to the reaction mixture. The reaction was stirred for 48 hrs at room temperature. The
resulting solution was dialyzed extensively with DMSO (dialysis membrane of molecular weight
cutoff = 1000 Da) for 24 h and with deionized water for 6 h. The obtained reaction mixture was
then lyophilized yielding 328.0 mg (0.0194 mmole) of intermediate 1 (G4-OH-Link-Boc). The
intermediate 1 contains Boc protected amino groups on the surface and it was characterized by
proton NMR. 1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.04 (bs, CO-NH, Boc), 7.92 (bs, CONH, G4-OH), 7.77 (bs, CO-NH, G4-OH), 4.69 (bs, OH, G4-OH), 3.96 (m, CH2OCO), 3.37-2.18
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(986H, m, aliphatic protons of G4-OH and CH2 of linker), 2.01 (m, CH2, methylene protons of
linker), 1.45 (m, 2 × CH2, methylene protons of linker), 1.34 (s, 3 × CH3, methyl groups of Boc).
To obtain free amine groups, 6.0 mL of TFA:DCM (1:1) was added to 328.0 mg G4-OH
conjugate containing Boc groups at 0°C. The reaction was carried out for 1 h at 0°C, and then the
solvent was removed at reduced pressure. The mixture was re-dissolved in DMSO and dialyzed
with DMSO for 24 h and deionized water for 6 h. The reaction mixture was then lyophilized
yielding 220 mg of bifunctional dendrimer 2. The conjugate 2 was characterized by proton
NMR. 1H NMR (DMSO-d6, 400 MHz): δ (ppm) 7.92 (bs, CO-NH, G4-OH), 7.77 (bs, CO-NH,
G4-OH), 4.69 (bs, OH, G4-OH), 3.99 (t, CH2OCO), 3.40-2.47 (986 H, m, aliphatic protons of
G4-OH and CH2 of linker), 2.31 (m, CH2, methylene protons of linker), 1.53 (m, 2 × CH2,
methylene protons of linker).

Figure 5. Synthesis of bifunctional PAMAM dendrimer (G4-OH-Link-NH2, 2).
2.3.11 Synthesis of Erythromycin-2′′-Glutarate (EM-2′′-glutarate, 3)
The reaction scheme is shown in Figure 6. Glutaric anhydride (31.09 mg, 0.272 mmole)
and TEA (30 µL) were added to a solution of EM (100 mg, 0.136 mmole) in 80:20 (v/v)
anhydrous DMF/DMA (10 mL). The reaction mixture was allowed to stir for 24 h under N2 and
additional 15.54 mg (0.136 mmole) of glutaric anhydride and TEA (30 µL) was added. The
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reaction mixture was continued to stir and was monitored with TLC. After 3 days of stirring,
TLC (methanol/ethyl acetate/DCM = 5:2:2, Rf = 0.4) showed that reaction was complete. The
reaction mixture was evaporated under reduced pressure and pure EM-2′-glutarate was isolated
by flash column chromatography on silica gel using methanol/ethyl acetate/hexanes (5:2:2) as
mobile phase (100 mg, yield 86%).
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Figure 6. Synthesis of EM-2’-glutarate 3 and Erythromycin-2′-glutarate-N-succinimidyl ester 4.
EM-2′-glutarate was characterized by proton NMR, HPLC, and ESI MS. 1H NMR
(DMSO-d6, 400 MHz): δ (ppm) 5.07 (dd, J1=11.6 Hz, J2=2.4 Hz, 1H), 4.72 (dd, J1=4.8 Hz,
J2=0.9 Hz, 1H), 4.60 (d, J=7.6, 1H), 4.52-4.49 (m, 2H), 4.01-3.96 (m, 2H), 3.88 (d, J=9.6 Hz,
1H), 3.69 (s, 1H), 3.67 (dd, 1H), 3.44-3.36 (m, 2H), 3.22 (s, 3H), 2.89 (d, J=8.8 Hz, 1H), 2.84 (d,
J=7.6 Hz, 1H), 2.61 (dd, J1=11.2 Hz, J2=3.2 Hz, 1H), 2.287-2.13 (m, 8H), 2.11 (s, 6 H), 1.86 (t,
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J=6.8 Hz, 1H), 1.80-1.74 (m, 1H), 1.71-1.63 (m, 4H), 1.59-1.46 (m, 2H), 1.39-1.31 (m, 1H), 1.23
(s, 3H), 1.15-0.97 (m, 21 H), 0.81 (d, J=7.2 Hz, 3H), 0.72 (t, J=7.2 Hz, 3H). ESI MS (m/z): calcd
for C42H72NO16 [M-H]+ 846.4, found 846.8.
2.3.12 Synthesis of Erythromycin-2′′-Glutarate-N-Succinimidyl Ester, 4
The synthetic scheme is shown in Figure 6. EM-2′-glutarate (70.00 mg, 0.0825 mmole)
was dissolved in 70:30 (v/v) anhydrous ACN:DCM (5 mL) and TEA (50 µL) and Nhydroxysuccinimido-phosphate (SDPP) (39.00 mg, 0.1238 mmole) were added to the solution at
0ºC. SDPP was synthesized following the literature procedure.63 After 6 hours of stirring the
TLC (MeOH:EtOAc:DCM = 1:3:2, Rf = 0.48) showed that reaction was complete.. The reaction
mixture was concentrated under vacuum and the pure product was isolated by flash column
chromatography on silica gel using methanol/ethyl acetate/hexanes (1:5:1) as a mobile phase (67
mg, yield 85%). The ester (4) was characterized by proton NMR. 1H NMR (CDCl3, 400 MHz): δ
(ppm) 5.00 (dd, J1=11.2 Hz, J2=1.6 Hz, 1H), 4.84 (d, J=4.0 Hz, 1H), 4.82-4.76 (m, 1H), 4.56 (d,
J=7.2 Hz, 1H), 3.95-3.92 (m, 1H), 3.88 (d, J=9.2 Hz, 1H), 3.76 (s, 1H), 3.54-3.50 (m, 1H), 3.46
(d, J=7.2 Hz, 1H), 3.29 (s, 3H), 3.04 (d, J=7.2 Hz, 1H), 3.00 (d, J=9.6 Hz, 1H), 2.90-2.84 (m,
2H), 2.83-2.78 (m, 3H), 2.75-2.67 (m, 1H), 2.63 (bs, 4H), 2.57-2.49 (m,1H), 2.41-2.38 (m, 1H),
2.32 (s, 6H), 2.54-1.99 (m, 2H), 1.93-1.86 (m, 2H), 1.82-1.69 (m, 2H), 1.61-1.50 (m, 3H), 1.42
(s, 3H), 1.25-1.09 (m, 21 H), 0.86 (d, J=7.6 Hz, 3H), 0.80 (t, J=7.6 Hz, 3H).
2.3.13 Preparation of G4-PAMAM Dendrimer-EM Conjugate (Dendrimer - EM, 5)
The reaction scheme for the preparation of dendrimer-EM conjugate (5) is outlined in
Figure 7. To a stirring solution of bifunctional dendrimer 2 (64 mg, 0.0041 mmole) in anhydrous
DMSO (6.5 mL), TEA (10 µL) was added under nitrogen condition. To this solution EM-2′-
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glutarate-N-succinimidyl ester (67 mg, 0.0708 mmole) dissolved in anhydrous DMSO (5 mL)
was added and the reaction mixture was allowed to stir for overnight at room temperature. After
completion of the reaction, the reaction mixture was subjected to dialysis in DMSO (membrane
MW cut off = 1000 Da) for 24 hours and in deionized water for 6 hours. The obtained reaction
mixture was lyophilized to get final dendrimer-EM conjugate 5. The conjugate 5 was
characterized by proton NMR. 1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.05 (bs, CO-NH,
linker), 7.94 (bs, CO-NH, G4-OH), 7.79 (bs, CO-NH, G4-OH), 5.07 (d, J=12.4Hz, 1H, Ery), 4.94.5 (m, OH, G4-OH; 3H, Ery), 4.11 (m, 2H, Ery), 3.97 (m, CH2OCO, G4-OH), 3.88 (d,
J=12.4Hz, 1H, Ery), 3.70 (bs, 1H, Ery), 3.37-2.16 (m, 986 H aliphatic protons, G4-OH; CH2,
linker; 24H, Ery), 2.06-1.28 (m, 4H, linker; 9H, Ery), 1.22 (s, 3H, Ery-CH3), 1.14-0.96 (m, 21 H,
Ery-CH3), 0.80 (m, 3H, Ery-CH3),, 0.72 (m, 3H, Ery-CH3).

Figure 7. Synthesis of PAMAM G4-OH-Erythromycin (Dendrimer-EM, 5).
2.4 Results
2.4.1 Synthesis and Characterization of Bifunctional PAMAM Dendrimer, 2
Due to better reactivity of amine groups compared to hydroxyl groups, a bifunctional
dendrimer was prepared. The reaction scheme is shown in Figure 5. 5-Boc-amino-valeric acid
was used as a linker to provide protected NH2 groups. Generation four hydroxy-terminated
PAMAM dendrimer (G4-OH) was reacted with activated 5-Boc-amino-valeric acid in presence
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of EDC and catalytic amount of DMAP to yield intermediate 1. The intermediate was confirmed
by proton NMR chemical shift and integration of Boc protected groups (s, 1.34 ppm, 9H), as
well as chemical shifts of methylenes that belong to the linker (m, 1.45 ppm, 4H) and dendrimer
ester methylenes

(m, 3.96 ppm, CH2OCO) that appear after conjugation (Figure 8). The

integration of characteristic peaks for Boc groups and amide peaks of dendrimer obtained from
NMR spectrum suggested that 13 molecules of Boc-linker were conjugated to the dendrimer.

Figure 8. Proton NMR of intermediate 1 (G4-OH-Link-Boc).
The deprotection of Boc-protected amino groups in mild condition, TFA:DCM (1:1),
gave bifunctional dendrimer 2 which consists of 54 hydroxyl and 10 amine groups. The slightly
lower number of NH2 groups (10 instead 13) are most probably due to hydrolysis of ester bond.
The number of amine groups was determined based on proton NMR from integration of
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characteristic peaks for methylene protons that belong to the linker (m, 1.45 ppm, 4H) and amide
protons of dendrimer (Figure 9).

Figure 9. Proton NMR of bifunctional PAMAM dendrimer (G4-OH-Link-NH2, 2).
2.4.2 Synthesis of G4-PAMAM Dendrimer-EM Conjugate, 5
The amino groups of bifunctional dendrimer were conjugated to EM-2′-glutarate through
stable amide bond (Figure 7). Prior to conjugation of dendrimer with EM-2′-glutarate, EMglutarate-N-succinimidyl ester was prepared.63 EM consists of a 14-membered lactone ring with
ten asymmetric centers, and glycosylated in two positions by desosamine and cladinose sugars.64
Cladinose is linked to the 4-position while desosamine to the 6-position of the lactone ring. EM
also contains four hydroxyl groups that differ in their reactivities. The order of reactivity was
established by acetylation. The most reactive hydroxyl group is at 2′-position where acetylation
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occurs first due to vicinity of tertiary amine that acts as an autocatalyst.65,66 When limiting
amount of acetic anhydride is used, the 2′-monoacetate would be the only product, and it can be
obtained without any catalyst. The tertiary amine group also increases the rate of 2′-monoacetate
hydrolysis, which can be achieved by quenching the reaction with methanol. The second most
reactive hydroxyl group is at 4′′-position, while the third one is at 11-position. The reaction of
EM with glutaric anhydride in the presence of triethylamine occurred at 2′-position which gave
EM-2′-glutarate 3 and was characterized by HPLC, proton NMR, and mass spectroscopy. The
molecular weight of 3 from mass spectrum [M-H]+ was found to be 846.8 which is in agreement
with calculated one, 846.4 (Figure 10).

Figure 10. ESI MS of Erythromycin-2′-glutarate (EM-2’-glutarate) 3, (m/z): calc. for
C42H72NO16 [M-H]+ 846.49, found 846.79.
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Analysis of proton NMR spectrum showed that th chemical shifts of H-1′ (d, 4.60 ppm, J=7.6
Hz), H-2′ and H-3′ (m, 4.52-4.49 ppm) of desosamine as well as overlapping signals for
methylene protons that belong to the glutarate moiety and EM (m, 1.71-1.63 ppm and m, 2.282.13 ppm) confirmed the formation of EM-2′-glutarate (Figure 11).

Figure 11. Proton NMR of Erythromycin-2′-glutarate (EM-2′-glutarate) 3.
The HPLC chromatograms showed that the retention times for EM and EM-2′-glutarate were
22.08 and 23.66 min respectively (Figure 12). EM-2′-glutarate was then reacted with SDPP in
the presence of triethylamine to obtain activated ester of Erythromycin 4. The ester was
characterized by proton NMR showing characteristic peak for methylene protons of succinimide
ester (s, 2.63 ppm, 4H) (Figure 13). We achieved better yield when SDPP was used compared to
N-hydroxysuccinimide. The activated ester of EM was coupled with bifunctional dendrimer to
yield dendrimer-EM conjugate.
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Figure 12. HPLC chromatograms of Erythromycin, and Erythromycin-2′-glutarate (3) at 210
nm.

Figure 13. Proton NMR of Erythromycin-2′-glutarate-N-succinimidyl ester 4.
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Dendrimer-EM conjugate was characterized by HPLC and compared to bifuctional
dendrimer and G4-OH as shown in Figure 14. The analysis of HPLC spectra showed that the
retention time of G4-OG (7.96 min) was very close to bifunctional dendrimer (8.13 min), since
there is no significant difference in chemical structure. However, the dendrimer-EM and G4-OHLink-Boc intermediate gave very distinct broad peaks at 11.69 and 13.13 min, respectively. The
broad peaks are due to larger size and non-polar character of conjugates compared to G4-OH and
bifunctional dendrimer.

Figure 14. HPLC chromatograms of G4-OH, bifunctional dendrimer G4-OH-Link-NH2 (2),
Dendrimer-EM conjugate (5), and G4-OH-Link-Boc (1) at 210 nm.
The proton NMR of dendrimer-EM conjugate is shown in Figure 15. Comparison of the
integration of amide peaks of dendrimer and methyl groups of EM revealed that four molecules
of EM were attached to the surface of the dendrimer.
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Figure 15. Proton NMR spectrum of dendrimer-EM (5) in DMSO-d6.

MALDI-TOF MS spectra of dendrimer-EM were evaluated and compared with G4-OH
which is shown in Figure 16. The obtained molecular weight of dendrimer-EM conjugate
(18,203.6), also suggests that a payload of approximately four molecules of EM was achieved.
This represents a drug payload in the conjugate of ~16% by weight, which is relatively high for a
polymer-drug conjugate. The conjugate was soluble in PBS buffer pH 7.4, in contrast to the free
drug.
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Figure 16. MALDI-TOF MS spectra of (a) dendrimer-EM (5), and (b) G4-OH dendrimer.

2.4.3 Particle Size and ζ-Potential
Zeta potential and size of the nanoparticle or drug molecule plays a major role in
targeting and delivery to the specific site. It is also influences the binding properties of the drug
and dendrimer/nanoparticle to the receptor. We have investigated particle size and zeta potential
of G4-OH, bifunctional dendrimer (2) and dendrimer-EM conjugate (5) which are shown in
Table 2. We did not find much difference in size between G4-OH, G4-OH-Link-Boc and
bifunctional dendrimer (2); this may be due to minimal difference in molecular weight of these
molecules. The dendrimer-EM conjugate has slight larger size (4.98 nm) compared to others.
The G4-OH has less cytotoxicity due to its neutral surface charge. It has slightly positive zeta
potential (4.54 mV) which is due to the presence of tertiary amines in its core even though it
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suppose to have neutral value. We did not find any difference between G4-OH and G4-OH-LinkBoc, but there is a difference between G4-OH and G4-OH-Link-NH2 (2). This is due to an
increase in number of primary amine (12-13 groups) on the surface of the dendrimer after
deprotection of Boc groups (6.29 mV). The zeta potential of dendrimer-EM conjugate is 8.08
mV. The tertiary nitrogen groups of erythromycin are responsible for slightly higher value of
dendrimer-EM compared to G4-OH and bifunctional dendrimer.
Table 2. Particle size and ζ-potential of dendrimer conjugates
Compound
Diameter (nm)
ζ-potential (mV)
G4-OH
G4-OH-Link-Boc
G4-OH-Link-NH2
Dendrimer-EM

4.28±0.24
4.53±0.30
4.22±0.28
4.98±0.50

+4.54±0.10
+4.92±1.20
+6.29±2.50
+8.08±0.90

2.4.4 Release Studies
The drug release rate of the conjugate was carried out in PBS buffer at pH 7.4 and
analyzed by HPLC. The ester linkage used for conjugation of EM was susceptible to hydrolysis
and about 90% of the EM was released within 10 hours (Figure 17). EM release from the
conjugate was completed within 20 hours. There are two ester links in the dendrimer-EM
conjugate, and the release study clearly showed that ester bond on the 2′-position releases
preferentially. This is consistent with the previous studies where EM-2′-monoacetate easily
hydrolyzes when the reaction quenched with methanol due to vicinity of tertiary amine group.
This tertiary amine group acts as an autocatalyst for the hydrolysis of ester bond.65,66
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Figure 17. Drug release profile of dendrimer-EM conjugate (5) in PBS buffer pH 7.4.
To confirm that the EM release was due to hydrolysis of the ester linkage another control
experiment was carried out. The conjugate was dissolved in anhydrous DMSO and the stability
was analyzed for 24 hours. The conjugate was completely stable in anhydrous condition and did
not release any EM. The drug release from the conjugate followed pseudo-first order reaction
kinetics (k’ = 0.36 h-1, t1/2 = 1.9 hrs) as determined by plotting natural logarithm of ester linked
EM against time (Figure 17). The rate constant was determined from the linear regression of this
graph where the slope of the line is the reaction rate constant. This release profile is very
appropriate for the present application and it is anticipated that the dendrimer will transport the
drug inside cells and release it over a period of several hours.
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2.4.5 The Cytotoxicity of Dendrimer-EM Conjugates on RAW 264.7 Macrophages
In order to assess the efficacy, it was important to show that the conjugate was non
cytotoxic. The concentrations of EM in the X-axis are on drug basis (Figure 18). The free
dendrimer concentration was based on the amount of dendrimer present in the dendrimer-drug
conjugate, at the indicated EM concentration. For example, at the highest concentration of EM
(10 µg/mL), is equivalent to ~60 µg/mL of dendrimer-EM conjugate. Therefore, 50 µg/mL of the
free dendrimer was used as control.

Figure 18. Effect of dendrimer-EM conjugate (5) on the release of LDH in LPS-stimulated
RAW 264.7 cells. Three independent experiments were performed, and data are mean ± SD of
six samples per group.
As shown in Figure 18, free dendrimer, EM and dendrimer-EM conjugate did not show
appreciable cytotoxicity in LPS activated RAW 264.7 cells at the concentrations up to 10 µg/mL
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for a treatment period of 48 hours, based on the LDH assay. Since these are the same activated
cells on which the efficacy is tested, the non-cytotoxic behavior of the compounds suggests that
the efficacy reported is primarily due to the anti-inflammatory activity.
2.4.6 Dendrimer-EM Conjugate Inhibited NO Production
RAW 264.7 cells were cultured with LPS (1 µg/mL) in the presence of dendrimer-EM for
48 hours, a concentration-dependent inhibition of NO2- generation was observed (Figure 19).
These macrophages are the in vivo targets in the orthopedic applications envisages for these
conjugates. The stimulation by LPS causes the macrophages to release the inflammatory
markers, suppression of which would be a measure of efficacy. As shown in Figure 19,
dendrimer-EM significantly inhibited NO2- release, as compared with untreated cells, and
EM-treated

cells

at

the concentration of 1-10 µg/mL. Interestingly, we also noticed that

dendrimer-EM demonstrated much stronger NO2- production inhibition than free EM at the
dosage range of 5-10 µg/mL. The improved in vitro activity of the dendrimer-EM conjugate
where the drug and the dendrimer are ester-linked is significant, since polymer-drug conjugates
for cancer applications typically show lower activity in vitro, compared to free drug.18,31 This
suggests that enabling an effective intracellular drug release profile (as shown in Figure 17) is
crucial for improved efficacy. The improved anti-inflammatory activity of the conjugate is
qualitatively comparable to the improvements in the activity of dendrimer-N-acetyl cysteine
conjugates with glutathione sensitive linkers.25
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Figure 19. Effect of dendrimer-EM conjugate (5) on LPS-induced nitric oxide production in
RAW 264.7 cells. Five independent experiments were performed, and data are mean ± SD of six
samples per group. * p< 0.05 EM vs. dendrimer-EM, ** p< 0.05 EM, and dendrimer-EM vs.
LPS group.

2.4.7 Dendrimer-EM Conjugate Still Preserves Its Antibacterial Activity
The antibacterial activity of the dendrimer-EM conjugate at different concentrations is
shown in Figure 20. Based on a zone of inhibition evaluation, the dendrimer-EM conjugate
showed similar activity, as compared to free EM with the same concentration. Furthermore, free
dendrimer did not show any effect of bacterial inhibition at the concentration up to 0.2 mg/mL.
This suggests that, either conjugation to dendrimers did not affect the antibacterial activity of
EM, or free EM was released from the conjugate within the 24 hour period. It is most likely the
latter, since the drug releases from the conjugate appreciably over this period (as shown in the
release data). Of course, it is not clear if the EM is released outside the bacteria and is taken up
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as free EM, or if the conjugate is internalized and the drug is released inside the cell. The results
suggest that the conjugation to dendrimer did not negatively affect the antibacterial activity,
while producing a superior anti-inflammatory activity.

Figure 20. Zone inhibition induced by EM at different concentration. (A) Disk papers soaked
with the PBS solution containing different concentration of dendrimer, EM and dendrimer-EM
conjugate were put into a bacterial agar plate (inoculated with the bacteria strain of S. aureus for
the zone of inhibition test. The bacteria plates were incubated for 24 hours, and then the diameter
of the zone of growth inhibition around each disk to the nearest whole mm were measured. (B)
Quantitative analysis of the size of zone of inhibition (mm) among different compounds. All the
tests were performed in triplicate, and repeated two times.
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2.5 Discussion
In recent years, dendrimer-based nanocarriers have been extensively used for drug and
gene delivery. The drugs are attached to dendrimer surface functional groups either directly or
via spacers, and very often with targeting moiety (ligand to receptor). The most common bonds
are ester and amide, which can be hydrolyzed inside the cell by endosomal or lysosomal
enzymes. The drug release due to hydrolysis is governed by the pH, and ester bonds are more
labile towards the hydrolysis compared to amide bonds.22 Studies have shown that ester-linked
conjugates can be hydrolyzed by esterase enzymes in human plasma, while amide bonds are
quite stable.23,24 A key challenge for dendrimer-drug conjugates is to engineer systems where
the drug is released over a time scale appropriate for the application.
In this study, a neutral PAMAM dendrimer-EM conjugate was prepared and evaluated
for its anti-inflammatory and antibacterial activity. The hydroxy-terminated PAMAM
dendrimers are more biocompatible and significantly less cytotoxic than the amine-terminated
counterparts.67 PAMAM G4-OH was reacted to a protected amine linker followed by
deprotection to obtain a bifunctional dendrimer that contains 10-15% amine groups. EM was
modified to EM-2’-glutarate and conjugated to the bifunctional dendrimer through an amide
bond. A combination of HPLC, proton NMR and MALDI-TOF analyses showed that the
conjugates were ‘pure’ with a drug payload of ~16% by weight, which is relatively high for
polymer conjugates, yet was very soluble in PBS buffer. The conjugate released the drug
effectively, with more than 90% of free drug over a period of 10 h. The efficient release of drug
from 2’-position of EM preferentially is due to tertiary amine group present in the vicinity of 2′position in EM. The conjugate was non cytotoxic to RAW 264.7 macrophages (the target cells
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for anti-inflammatory activity), and showed improved efficacy over free drug. In LPS activated
macrophages, the conjugate was more effective in reducing nitrite production (a measure of antiinflammatory activity) compared to free drug. The antibacterial activity of the conjugate was
comparable to free drug.
Our study indicated that the dendrimer-EM conjugates have a high drug payload (16%),
and improve the solubility of the drug, and could lead to improved activity. These are especially
important in delivering sufficient amount of EM to the site of periprosthetic inflammation and
reducing local inflammation in a sustained manner.
2.6 Future Work
2.6.1 In Vivo Efficacy of Dendrimer-EM Conjugate
Since dendrimer-EM showed an improved efficacy in vitro compared to free EM, an in
vivo study can be demonstrated using BALB/C mouse osteolysis model. Dr. Ren and his group
used this model to evaluate in vivo efficacy of free EM.59 It is created by introducing the
ultrahigh molecular-weight polyethylene (UHMWPE) into established air pouches on BALB/c
mice where UHMWPE debris induces tissue inflammation. A preliminary study was done by Dr.
Ren in collaboration with our group where these mice were treated with dendrimer-FITC
conjugates (Figure 21). As it can be seen from the images dendrimers showed to have an affinity
for preferential accumulation in areas associated with periprosthetic inflammation. Based on
these results we can expect that dendrimer-EM nanodevices can lead to improved in vivo
efficacy that is the delivering of sufficient amount of EM using dendrimer as a vehicle to the site
of periprosthetic inflammation and the local inflammation could be reduced in a sustained
manner.
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Figure 21. BALB/C mice, osteolysis model, treated with: (A) PAMAM dendrimer-FITC (green)
- intraperitonial administration, (B) Saline solution with free FITC - intravenous administration,
and(C) PAMAM dendrimer-FITC (green) - intravenous administration.
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CHAPTER 3 “PAMAM DENDRIMER-BASED DIAGNOSTIC NANODEVICES FOR
IMPROVED DETECTION OF TNF-α CYTOKINE”

3.1 Abstract
A novel dendrimer-based sandwich type enzyme-linked immunosorbent assay (ELISA)
kit was developed for the detection of recombinant human tumor necrosis factor-alpha (TNF-α).
Hydroxyl terminated generation four poly(amidoamine) dendrimer (PAMAM-OH) was used for
the development of a solid phase bio-sensing platform. The surface of the ELISA plate was
modified with polyethylene-glycol (PEG) by reacting PEG-maleimide and PEG-hydroxy to get
maleimide reactive surface groups. A thiol functionalized PAMAM-OH was synthesized and
immobilized on the PEG-functionalized assay plate and the remaining thiol groups of dendrimer
were converted to hydrazide groups. A capture antibody was oxidized and covalently
immobilized onto dendrimer-modified ELISA plate which gives antibody favorable orientation
for the antigen binding sites toward the analyte. The dendrimer modified plate showed enhanced
sensitivity and the detection limit for TNF-α was found to be 0.48 pg/mL, which is significantly
better than the commercially available ELISA kit. The selectivity of the dendrimer-modified
ELISA plate was examined by studying TNF-α in a mixture of cytokines which gave similar
results. Dendrimer-modified ELISA plate provides a greater opportunity for the detection of a
wide range of cytokines and biomarkers.
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3.2 Introduction
One of the greatest challenges faced by modern perinatal medicine is preterm birth (PTB)
and perinatal morbidity. Intra-amniotic infection/inflammation (IAI) is one of the most important
causes of preterm birth. The relationship between IAI and preterm labor has been well
established.68 It accounts for 75% of perinatal mortality and 50% of perinatal morbidity.69,70
Early detection of the infection is also challenged by the sub-clinical nature of the disease.71,72
Fever, uterine tenderness and fetal tachycardia occur late in pregnancy and present in small
portion (12.5%) of the women with microbiological evidence of infection.73,74 An elevated level
of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, and MMP-8) are found in infected intraamniotic fluid, which are biomarkers for early detection.75,76 The development of sensitive and
specific diagnostic device which will enable an early detection and treatment to prevent fetal
damage would be of great interest. The importance of detection of these cytokines is also
enhanced by their association with pulmonary and neurodegenerative diseases. There are plenty
evidence to prove the presence of an elevated level of TNF-α in the patients suffering from
Alzheimer's disease77, Parkinson’s disease78, Multiple Sclerosis79 and Chronic Obstructive
Pulmonary disease (COPD)80.
TNF-α is a pro-inflammatory cytokine that regulates the immune system inducing
inflammation and apoptosis in many organs of the body. In the brain, overexpression of TNF-α
in microglia cells causes neural death which is linked with neurological disorders. An increased
level of TNF-α is also associated with pre-term birth and cerebral palsy.81 Therefore, determining
the level of TNF-α in amniotic fluid is essential for an understanding of the mechanism of preterm birth and its prevention. Enzyme-linked immunosorbent assay (ELISA) is the most
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common method used to determine the concentration of TNF-α. In literature, beside the ELISA,
various methods have been reported for determination of TNF-α concentration. These methods
include radioimmunoassays (RIA),82 bioassays,83 chemiluminescence84 and chemiluminescence
imaging85, matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS)86,
immuno-PCR87 and immuno-PCR assay88, fluorescence immunoassay89, and electrochemical
immunosensor90. The detection limits for cytokines of currently used immunosensors are at a
much higher level of concentration. Our goal is to develop a diagnostic device that will detect the
presence of TNF-α at a lower level by improving its sensitivity and specificity. The solid-liquid
interface results in sensitivity, and interaction at the analyte-ligand provides selectivity and
stability.91 In developing an immunosensor, the immobilization of antibodies is a key step. The
antibodies should be immobilized onto a substrate at high density with uniform distribution
followed by retaining their specific antigen-binding activities, and finally maintaining
accessibility to the antigens.16 The aim is to develop a biosensor which will maximize the
biochemical activity and minimize nonspecific protein adsorption. In effort to improve the
existing detecting devices, use of dendrimers could play a very important role.
Unlike linear polymers, dendrimers do not form entangled chain but unique in shape with
numerous chain ends which can be functionalized. They are stable, can be closely packed on the
substrate surface, and have multiple branch ends available for further conjugation.92,93
Dendrimers have all the specification to be used in next generation of biosensors.8,94 Dendrimers
have been recently reported to significantly increase binding ability and homogeneity in DNA
microarray analysis.11,95,96 Dendrimers are also utilized in electrochemical immunosensor,13,97
biosensor-based encapsulated Platinum nanoparticles,9,98 regenerable affinity-sensing surfaces15
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and surface plasmon resonance biosensor99. The application of dendrimer is extended to
preparation of metal-dendrimer nanocomposites using PAMAM dendrimers with various
terminal groups.100-101 Carboxyl terminated PAMAM dendrimers have shown to lower the
nonspecific cellular protein adsorption and enhancing antibody binding properties.16
Recently we have reported a highly sensitive dendrimer-based biosensing platform for
IL-6 and IL-1β cytokines detection in which pegylated ELISA plate was modified using amine
terminated PAMAM dendrimer.17 In continuing our effort, we have developed a solid phase
biosensing platform using generation four hydroxyl terminated PAMAM dendrimer for TNF- α
cytokine detection. The synthesis, characterization, fabrication and functional evaluation of this
biosensing platform for TNF-α detection is described in this Chapter. The plate surface was coimmobilized with hydroxyl polyethylene glycol (NH2-PEG-OH) and maleimide PEG (NH2PEG-Mal). Maleimide PEG was covalently linked to PAMAM dendrimers on the surface of the
plate leading to controlled dendrimer grafting density which is also responsible for the increased
grafting density of the antibody. The modified ELISA plate with long PEG arms and
functionalized-dendrimer provides diffusional and conformational flexibility, which gives more
favorable antibody-antigen interactions. The resulting dendrimer functionalized plate was
employed as template to immobilize the anti-human TNF-α antibody and the performance was
evaluated by the detection of TNF-α using TMB detection method. The dendrimer-based assay
was compared to commercially available TNF-α kit.
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3.3 Materials and Methods
3.3.1 Materials
Hydroxyl terminated generation four poly(amidoamine) dendrimer (G4-OH) was
obtained from Dendritech Inc. N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride
(EDC), 4-(dimethylamino)pyridine (DMAP), N-succinimidyl-3-(2-pyridyldithio)-propionate
(SPDP), tris(2-carboxyethyl) phosphine (TCEP) and MALDI-TOF mass reference standards
were purchased from Sigma-Aldrich. Trifluoroacetic acid (TFA) was obtained from EMD
Chemicals.

Hydoxyl

terminated

Polyethylene glycol

(NH2-PEG-OH,

2.0

kDa) and

maleimide terminated PEG (NH2-PEG-Mal, 3.4 kDa) were obtained from JenKem Technology,
Beijing, China and Creative PEGworks, Winston Salem, USA respectively. DMSO-d6 was from
Cambridge Isotope Laboratories. Anhydrous DMSO and dichloromethane (DCM) were from
Acros Organics, USA. N-(ε-maleimidocarproic acid) hydrazide (EMCH) was from Pierce. All
other solvents and chemicals used were from Fisher Scientific. Regenerated cellulose (RC)
dialysis membrane (molecular weight cut-off 1000 Da) was obtained from Spectrum
Laboratories. Recombinant human TNF-α, monoclonal TNF-α anti-human antibody, biotinylated
anti-human TNF-α antibody, streptavidin-HRP (DY998), reagent diluent (DY995), substrate
reagent (TMB, DY999), stop solution (DY994) and wash buffer (WA126) were obtained from
R&D Systems. ELISA plates were purchased from Corning (high bind plate).
3.3.2 NMR Spectra Analysis
NMR spectra were recorded on a Varian INOVA 400 spectrometer using DMSO-d6.
Proton chemical shifts are reported in ppm (δ) and tetramethylsilane (TMS) used for internal
standard.
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3.3.3 MALDI-TOF Mass
Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectra
were recorded on a Bruker Ultraflex system. Cytochrome C (MW 12,361 g/mol), and
Apomyoglobin (MW 16,952 g/mol) were used as external standards. A dendrimer solution was
prepared by dissolving 2 mg of dendrimer in 1 mL of DMSO. The matrix solution was prepared
by dissolving 20 mg of trans-3-indoleacrylic acid matrix in 1 mL of the 1:1 mixture of deionized
water and acetonitrile (0.1% TFA). Analytical samples were prepared by mixing 10 µL of
dendrimer solution with 100 µL of matrix solution, followed by deposition of 1 µL of sample
mixture onto a 384-well aluminum plate. This mixture was allowed to air dry at room
temperature. All data processing was performed using Bruker Daltonics flexAnalysis software.
3.3.4 HPLC
High performance liquid chromatography (HPLC) characterization was carried out using
Waters HPLC instrument. Two pumps, an auto-sampler and dual UV detector are interfaced to
Breeze software. The HPLC chromatogram was monitored at 210 and 238 nm simultaneously
using the dual UV absorbance detector. H2O:ACN (0.14% TFA) was used as mobile phase. Both
phases were freshly prepared, filtered, and degassed prior to use. Symmetry300 C18 reversephase column (5 µm particle size, 25 cm × 4.6 mm length × I.D.) equipped with a Supelguard
Cartridges (5 µm particle size, 2.0 cm ×3.9 mm length × I.D.) was used for characterization of
the conjugates. HPLC analysis was done using 90:10 to 30:70 (H2O:ACN) gradient flow in 30
minutes with flow rate of 1 mL/min.
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3.3.5 Synthesis of Bifunctional G4 PAMAM-OH-PDP Dendrimer
The reaction scheme for the preparation of the bifunctional G4 PAMAM-OH-PDP is
outlined in Figure 22. The 5-(Boc-amino)valeric acid (228.2 mg, 1.0504 mmole) was dissolved
in DMSO (10 mL), then EDC (603.8 mg, 3.15 mmole) and DMAP (12.0 mg, 0.0982 mmole)
were added under nitrogen atmosphere. The mixture was allowed to stir for 1 hour at room
temperature and PAMAM G4-OH (500.0 mg, 0.0350 mmole) dissolved in DMSO (5 mL) was
added to the reaction mixture. The reaction was stirred for 48 hours at room temperature. The
resulting solution was dialyzed extensively with DMSO (dialysis membrane of molecular weight
cutoff = 1000 Da) for 24 hours and with deionized water for 6 hours. The obtained reaction
mixture was then lyophilized yielding 445.0 mg (0.0242 mmole) of G4-OH-Link-Boc
intermediate. This intermediate contains Boc protected amino groups on the surface. 1H NMR
(DMSO-d6, 400 MHz): δ (ppm) 8.04 (bs, CO-NH, Boc), 7.92 (bs, CO-NH, G4-OH), 7.77 (bs,
CO-NH, G4-OH), 4.69 (bs, OH, G4-OH), 3.96 (m, CH2OCO), 3.37-2.18 (986H, m, aliphatic
protons of G4-OH and CH2 of linker), 2.01 (m, CH2, methylene protons of linker), 1.45 (m, 2 ×
CH2, methylene protons of linker), 1.34 (s, 3 × CH3, methyl groups of Boc).

Figure 22. Synthesis of G4 PAMAM-OH-PDP dendrimer .
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The deprotection of Boc protected amino groups was done by adding 6.0 mL of TFA:DCM (1:1)
to 445.0 mg of G4-OH-Link-Boc in a round bottom flask at 0oC. The reaction was carried out for
1 hour at 0 °C, and then the solvent was removed at reduced pressure. The mixture was redissolved in DMSO and dialyzed with DMSO for 24 hours and deionized water for 6 hours. The
reaction mixture was then lyophilized yielding 298 mg of bifunctional dendrimer. 1H NMR
(DMSO-d6, 400 MHz): δ (ppm) 7.92 (bs, CO-NH, G4-OH), 7.77 (bs, CO-NH, G4-OH), 4.69 (bs,
OH, G4-OH), 3.99 (t, CH2OCO), 3.40-2.47 (986 H, m, aliphatic protons of G4-OH and CH2 of
linker), 2.31 (m, CH2, methylene protons of linker), 1.53 (m, 2 × CH2, methylene protons of
linker). Then the bifunctional dendrimer (150.0 mg, 0.00937 mmole) was dissolved in 9 mL of
PBS, pH=7.4. To this SPDP (87.0 mg, 0.2798 mmole) in 3.5 mL ethanol was added. The
reaction mixture left to react for 2 hours at room temperature. The resulting solution was
dialyzed extensively with water (dialysis membrane of molecular weight cutoff = 1000 Da) for
24 hours. The obtained reaction mixture was then lyophilized yielding 90.0 mg (0.00529 mmole)
of G4 PAMAM-OH-PDP dendrimer conjugate. The conjugate was characterized by proton
NMR.

1

H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.43 (d, 1H, pyridyl H), 8.12 (bs, CO-NH,

linker, G4-OH), 7.98 (bs, CO-NH, G4-OH), 7.81 and 7.73 (m, pyridyl Hs), 7.22 (t, 1H, pyridyl
H), 4.75 (bs, OH, G4-OH), 3.98 (m, CH2OCO), 3.51-2.08 (m, 990H, aliphatic protons of G4OH, CH2 of linker, and CH2 of PDP.), 2.04 (m, CH2, methylene protons of linker), 1.48 (m, CH2,
methylene protons of linker), 1.36 (m, CH2, methylene protons of linker). MALDI-TOF (pos)
m/z 17141.1.
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3.3.6 Synthesis of EMCH Functionalized G4 PAMAM-OH-PDP Dendrimer
The reaction scheme of EMCH functionalized G4 PAMAM-OH-PDP synthesis is shown
in Figure 23. The G4 PAMAM-OH-PDP dendrimer (2.4 mg, 140 nmole) was dissolved in 1 mL
of PBS/EDTA buffer (pH 7.4, 5 mmole EDTA). To this solution, 0.80 mg of TCEP (2.80 µmole,
20 equiv.) in 1mL of PBS/EDTA buffer (pH 7.4, 5 mmole EDTA) was added. The reaction
mixture was evacuated, flushed with N2 and the reaction mixture was stirred for 15 minutes at
room temperature under N2 to get the free thiolated conjugate. Then the reaction mixture was
cool down to 0°C and 0.72 mg of EMCH (2.10 µmole, 15 equiv.) in 1 mL of PBS buffer was
added. The reaction mixture was reacted for 3 hours at room temperature under N2. The reaction
mixture was extensively dialyzed with water (dialysis membrane of molecular weight cutoff =
1000 Da) for 24 hours and lyophilized to give EMCH functionalized G4 PAMAM-OH-PDP
conjugate as a pale yellow oily solid. The EMCH functionalized G4 PAMAM-OH-PDP
conjugate was characterized by proton NMR. 1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.90 (s,
1H, hydrazide amide NH), 7.94 (bs, CO-NH, linker, G4-OH), 7.82 (bs, CO-NH, G4-OH), 4.8
(bs, OH, G4-OH), 3.95 (m, CH2OCO), 3.50-2.00 (m, 997H, aliphatic protons of G4-OH, CH2 of
linker, CH2CH2S CH CH2, NCH2, and NH2), 1.89 (m, CH2, methylene protons of linker, and
CH2NHNH2), 1.58-1.32 (m, CH2, methylene protons of linker, and CH2NHNH2 of EMCH), 1.301.05 (m, CH2, methylene protons of linker, and of EMCH).
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Figure 23. Synthesis of EMCH functionalized G4 PAMAM-OH-PDP as a model compound.
3.3.7 Modification of ELISA Plate with PEG
The solutions of EDC and HOBt in MES buffer (pH 6.5), 1mg/mL, were prepared. The
amounts of 75 µL of EDC solution and 60 µL of HOBt solution were added to each well of
ELISA plate (391 nmol of each per well). Then 10 µL of NH2-PEG-MeI (MW=3.4 kDa) in MES
buffer (pH 6.5), 12.52 µg/mL, was added to each well (7.4 pmole/well) and incubated for 30
minutes at room temperature. To each well 30 µL of NH2-PEG-OH (MW=2 kDa) was added,
5.81 mg/well. The plate covered with aluminum foil and left to incubate for 8 hours at room
temperature with constant shaking. Then ELISA plate was washed with PBS buffer (pH 7.4)
three times and with deionized water three times, dried under nitrogen, and stored at -20 ˚C.
3.3.8 Conjugation of G4 PAMAM-OH-PDP Dendrimer to Pegylated ELISA Plate
G4 PAMAM-OH-PDP dendrimer (1.2 mg, 70 nmole) was dissolved in 1 mL of
PBS/EDTA buffer (pH 7.4, 5 mmole EDTA). To this solution, 0.4 mg of TCEP (1.4 µmole, 20
equiv.) in 0.5 mL of PBS/EDTA buffer (pH 7.4, 5 mmole EDTA) was added. The reaction
mixture was evacuated, flushed with N2 and the reaction mixture was stirred for 15 minutes at
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room temperature under N2 to get the free thiolated conjugate. Then the reaction mixture was
transferred in glove box and cooled down to 0°C. To this 0.16 mg of EMCH (0.49 µmole, 7
equiv.) in 0.5 ml of PBS buffer was added and incubated for 20 minutes at 0°C. The amount of
10 µL of this reaction mixture was diluted to 31.5 mL with PBS buffer (pH 7.4) and 270 µL of
diluted solution was added to each well of pegylated ELISA plate (3 pmole/well). The plate was
sealed and incubated for 3 hours at room temperature in glove box with constant shaking. Then
10 µL of 2-mercaptoethanol in PBS (pH 7.4) was added to each well (1 µL of 2mercaptoethanol/well) and incubated for 1 hour at room temperature. The ELISA plate was
washed with PBS buffer (pH 7.4) four times and with deionized water four times, dried under
nitrogen, and stored at -20 ˚C.
3.3.9 Oxidation of Monoclonal Anti-Human TNF-α/TNFSF1 Antibody (MAB610) and Its
Immobilization to Dendrimer Modified ELISA Plate
The oxidation was done by using sodium periodate. 500 µg of MAB610 was dissolved in
1 mL of PBS (pH 7) buffer. To this 100 µL of NaIO4 solution in PBS (pH 7) added at 4˚C (5 µg
NaIO4 per 50 µg MAB610). The reaction mixture left to react for 15 min at 4˚C protected from
light. Then the reaction mixture was transferred to Amicon centrifuge filter tube and was
centrifuged for 30 min, at 4˚C, and 2500 rpm. The concentrated sample, approximately 60 µL
was diluted with PBS buffer (pH 7.4) to 1 mL and loaded to PD-10 column. The column was
equilibrated with PBS (pH 7.4) according the spin protocol. Then the column was centrifuged at
1000 G, and 4˚C for 2 min. The concentrated antibody was diluted to 11 mL with PBS buffer
(pH 8), and 270 µL added to each well of dendrimer modified ELISA plate (3 µg/well). The
ELISA plate was sealed and incubated for 3 hours at 4˚C with continuous shaking. Then 10 µL
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of NaCNBH3 solution in PBS buffer (pH 8) (1mg NaCNBH3 per 1 mL buffer) was added to each
well and incubated for 1 hour at 4˚C with continuous shaking. After 10 µL of ethanolamine
solution in PBS buffer (pH 8) (1µL ethanolamine per 1 mL buffer) was added to each well and
incubated for 30 min at 4˚C with continuous shaking. Antibody immobilized dendrimer modified
ELISA plate then washed with wash buffer (WA126) seven times to make sure that there are no
chemicals left. The plate dried by blotting it against clean paper towels. Then 300 µL of reagent
diluents added to each well. The plate was sealed, covered by aluminum foil and left overnight at
4˚C. Then the plate was washed again with wash buffer, dried in the same way as above and
made ready for assay to be performed, which has to be done immediately.
3.3.10 Assay Procedure
The ELISA plate was washed with wash buffer seven times (300 µl per well). Twelve
different dilutions (concentrations from 460-0 pg/mL) of TNF-α standard in reagent diluents
were prepared. 100 µL of each dilution were added per well in triplicate. The plate was sealed
and incubated for 2 hours at room temperature. Then each well was washed with 300 µL wash
buffer seven times. After the plate was dried by blotting it against clean paper towels, 100 µL of
biotinylated antihuman TNF-a detection antibody (BAF 210, 1 µg/mL in reagent diluents) was
added to each well. The plate was sealed and incubated for 2 hours at room temperature. The
plate was washed and dried again in the same way as above and 100 µL of streptavidinhorseradish peroxidase conjugate in reagent diluents was added to each well. The plate was
incubated for 30 min at room temperature avoiding light and washed again with wash buffer.
Then 100 µL of substrate solution was added to each well and incubated 30 min in the dark at
room temperature. To stop the color reaction 50 µl of stop solution (2N sulfuric acid) was added
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to each well without washing the plate. The absorbance was measured immediately using a plate
reader (Molecular Devices, SpectraMax M2) set at 450 and 570 nm.
3.4 Results and Disscusion
3.4.1 Synthesis of Bifunctional G4 PAMAM-OH-PDP Dendrimer
Previously published results indicate that many commercially available ELISA plates
have problem due to nonspecific protein adsorption.103 In order to reduce the non-specific protein
adsorption and to improve the specificity and sensitivity of immunoassay technique, the
hydroxyl-terminated G4-PAMAM dendrimer was used to prepare an assay platform for TNF-α
cytokine detection. A bifunctional dendrimer was prepared by modifying few hydroxyl terminal
groups of generation four PAMAM dendrimer (G4-OH) to reactive amine for this platform. The
detailed synthetic procedure for this modification was reported by our group previously.104 In
brief, the G4-OH was reacted with 5-Boc-amino-valeric acid to get Boc protected amine groups
followed by deprotection with trifluoroacetic acid to generate a bifunctional dendrimer (2)
having free amine groups on the surface. To be able to immobilize dendrimer on pegylated
ELISA plate, the resulting bifunctional dendrimer was conjugated with linker N-succinimidyl 3(2-pyridyldithio)-propionate (SPDP) through amide bond (Figure 22). SPDP provides a protected
thiol in the form of a disulfide bond. The conjugate was characterized by HPLC, proton NMR,
and MALDI-TOF mass. HPLC gave very broad peak at 9.55 min due to large size and low
polarity compared to starting dendrimers (Figure 24). The number of attached PDP groups to
dendrimer was determined by NMR (Figure 25) by integrating peaks related to dendrimer amide
and pyridyl hydrogens at 8.43 (d, 1H), 7.81 and 7.73 (m), and 7.22 (t, 1H) ppm. The integration
revealed that 10 molecules of PDP were attached to the surface of the dendrimer. This is in a
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good agreement with MALDI-TOF MS (Figure 26) which increased molecular weight indicates
also that 10 molecules of PDP were added to dendrimer.

Figure 24. HPLC chromatograms of G4-OH, bifunctional G4-OH-PDP dendrimer, and SPDP at
210 nm.

Figure 25. Proton NMR spectrum of G4 PAMAM-OH-PDP dendrimer in DMSO-d6.
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Figure 26. MALDI-TOF mass spectra of (A) bifunctional G4 PAMAM-OH-PDP dendrimer, and
(B) G4-OH dendrimer.
The disulfide bond of PDP linker was reduced by tris(2-carboxyethyl) phosphine (TCEP) to thiol
groups quantitatively.105 The resulting conjugate having free thiol groups was used in situ
without purification and reacted with seven equivalence of N-(ε-maleimidocarproic
acid)hydrazide (EMCH) which is going to be used for antibody capturing. The remaining thiol
groups were required for dendrimer immobilization onto PEG-ELISA plate by conjugation to
maleimide groups. In order to prove that thiol-maleimide conjugation reaction went through, a
model reaction was performed (Figure 23). Therefore, all the thiol groups were conjugated with
EMCH to give hydrazide functionalized dendrimer. To prevent possible side reaction, the thiolmaleimide conjugation reaction was carried out at 0°C. The structure of of EMCH functionalized
G4 PAMAM-OH-PDP conjugate

was confirmed by 1H NMR (Figure 27), which shows

characteristic hydrazide amide proton, NHNH2(C=O), at 8.90 ppm and no pyridyl hydrogens
from PDP.
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Figure 27. Proton NMR spectrum of EMCH functionalized G4 PAMAM-OH-PDP dendrimer.
3.4.2 Surface Modification of ELISA Plate with PEG and Dendrimer Immobilization
Due to nonspecific protein adsorption by commercially available ELISA plates, we
modified our plates with polyethylene glycol (PEG). It is found that the nonspecific adsorption
of proteins on the plate’s surface decreases with the increasing molecular weight of PEG chain.
On the other hand, by increasing PEG molecular weight the tethered chain density decreases due
to the exclusion volume of each chain on the surface.106 The ELISA plates were modified
according to the procedure reported in our previous study.17 PEG was linked to the carboxylic
acid functionalized 96 well polystyrene plates. The functionalization of polystyrene plate with
PEG was carried out under mild conditions to minimize ring opening side reaction. Carboxylic
acid groups of polystyrene plate were activated by EDC and 1-hydroxybenzotriazole hydrate
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(HOBt), Figure 28. The resulting HOBt activated carboxylic groups could be hydrolyzed under
desired mild conditions which minimized the ring-opening side reaction of the NH2-PEG-Mal.107
PEG-maleimide (NH2-PEG-Mal, MW 3.4k Da) and PEG-hydroxyl (NH2-PEG-OH, MW 2k Da)
were co-immobilized to improve the nonfouling character of the surface and also cover the
‘defects’ on the polystyrene plate.103 NH2-PEG-Mal groups were used for immobilization of
dendrimer. Two equivalents of NH2-PEG-Mal were reacted with activated carboxylic groups,
based on the calculated dendrimer grafting density, considering the yield of the amidation
reaction and the reduced reactivity of thiol-maleimide conjugation reaction in the presence of
TCEP.105 Thus, NH2-PEG-Mal grafting density reflects the dendrimer graft density on the
surface.

Figure 28. Schematic representation of ELISA plate modification with PEG and immobilization
of G4 PAMAM-OH-PDP dendrimer on PEG layer.
Dendrimer immobilization was carried out inside the glove bag under the constant flow of
nitrogen at 4°C for 3 hours. Then 2-thioethanol was added to react with unreacted maleimide
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groups. The dendrimer modified plates were washed, dried, and stored at -20°C. They can be
stable for several months with no signs of reduced reactivity, suggesting that the dendrimermodified plates are stable and have an appreciable life time.

3.4.3 Antibody Immobilization onto Dendrimer Modified ELISA Plate
Antibodies play a key role in diagnostic methods; therefore the way in which they are
immobilized is very important. Antibodies are proteins, also called immunoglobulins (Ig),
because they are related to the immunological system. Basically they are glycoproteins having
carbohydrate chains added to some of their amino acid residues. The amounts of carbohydrates
can vary (3-12%) depending on the type of antibody and they are attached to the protein through
N-linked glycosylation site. Most glycosylation sites are located in constant region (Fc) of the
heavy chain. Glycosylation of these sites has little if any effect on binding activity of
antibodies.108 The studies showed that steric-hindrance, denaturation of antibody, and its random
orientation lead to reduction of binding activity of an antibody.109 By controlling the orientation
of immobilized antibodies on the sensor surface and with decreasing steric-hindrance effects,
specificity and sensitivity of an immunosensor can be increased.
The efficacious antigen binding depends on antibody immobilization method. Currently
available methods often have disadvantages such as reduced antibody-antigen binding activity
mostly due to random antibody orientation, denaturation, or steric-hindrance.110 The easiest
method of antibody immobilization is adsorption on a solid surface. However, adsorbed
antibodies are randomly oriented and their antigen binding activity can be reduced due to
denaturation. The most common method for antibody immobilization is covalent coupling using
amino groups on antibody surface. The disadvantage of this method is random orientation that
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leads to nonspecific binding. Some methods employ chemical immobilization of the antibodies
by chemically modifying the carbohydrates on the Fc region of an antibody or selectively
reducing disulfide bond of the cysteine residue in the hinge region of the antibody. Other
methods use protein G and protein A for orientated immobilization that specifically bind to the
Fc region of an antibody. These methods are less stable than covalent methods.
Mouse anti-human TNF-α antibodies were immobilized by their oligosaccharide moieties
in the constant region to dendrimer hydrazide linker of modified ELISA plate following similar
procedure that we used for IL-6 and IL-1β immobilization (Figure 29).17

Figure 29. Schematic representation of antibody immobilization on the ELISA plate modified
with multifunctional dendrimer.
First, carbohydrate vicinal hydroxyl groups in the constant region of antibody were oxidized by
sodium periodate in PBS buffer (pH 7) to aldehyde groups. The number of oxidized sites
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generated by NaIO4 depends on pH, temperature, reaction time and the concentration of the
oxidizing reagent.111 Using Purpald test with formaldehyde as a calibrator, we examined the
degree of antibody oxidation (Figure 30).112 Mild oxidation conditions were chosen to preserve
the immunoreactivity of the antibody: 50 µg of MAB610 antibody in PBS pH 6.8 was oxidized
by 0.1 mg NaIO4 (0.47 mM) for 15 minutes at 4°C in the dark. According to Purpald test, under
these conditions, approximately 8 aldehyde groups per antibody were obtained.

Figure 30. Standard curve of formaldehyde purpald test.
The aldehyde groups are required for the reaction with dendrimer hydrazide end group to form
hydrazone linkage. After oxidation, antibody was quickly separated from the oxidizing reagent
by the Amicon® centrifugal filter tube, and gel filtration with concomitant buffer exchange. The
purified oxidized antibody was dissolved in PBS buffer pH 8 and allowed to react with
dendrimer on ELISA plate at 4ºC for 3 hours, where hydrazone Schiff base was obtained.
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Because Schiff base is unstable, in situ reductive amination with sodium cyanoborohydride in
PBS buffer pH 8 was performed and hydrazone linkage was transformed into a stable secondary
amine linkage.113 The reaction was completed by adding ethanolamine to block unreacted aldehyde groups.
3.4.4 ELISA evaluation of dendrimer-modified surface
To evaluate the diagnostic performance of the dendrimer-based assay, recombinant
human TNF-α were assayed by the sandwich ELISA format using biotinylated goat anti-human
TNF-α as detection antibodies, streptavidin-HRP as a reporter and substrate tetramethylbenzidine
(TMB), Figure 31. Various known standard concentrations of TNF-α in the range of 0-250
pg/mL were assayed and typical dose-response curve was acquired. The reaction time between
antibodies on the sensor and the cytokines was 2 hours, and was the same as that for the kit plate.
These data were compared with commercially available TNF-α ELISA kit, and a plate coated
with mouse anti-human TNF-α capture antibodies, which were attached by physical adsorption
(Figure 32).
The linear regression equation for dendrimer plate for TNF-α was A = 0.1502 +
0.0037*C[TNF-α], with the linear regression coefficient R = 0.996. The sensitivity of dendrimer
plate for TNF-α detection (TMB) was determined to be 0.48 pg/mL (Table 3). Various methods
have been developed for determination of TNF-α level including ELISA, RIA,82 bioassays,83
chemiluminescence84 and chemiluminescence imaging,85 MALDI-MS,86 immuno-PCR87 and
immuno-PCR assay,88 fluorescence immunoassay,89 and electrochemical immunosensor90.
Dendrimer based assay in present study has a detection limit superior to that of other previously
reported TNF-α assay except that obtained by Hun et al. which used fluoroimmunoassay method.
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Figure 31. Schematic representation of TNF-α assay using dendrimer modified ELISA plate.

Figure 32. Standard curves for TNF-α ELISA measured with the dendrimer plate, TNF-α kit
plate, and the plate prepared by physical adsorption of antihuman TNF-α antibody.
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Dendrimer modified plate showed ~3 fold improvements on the detection limit compare to kit
plate for TMB detection (0.48 pg/mL vs. 1.28 pg/mL). This result suggests that dendrimer
conjugation reactions to the antibody preserved the activity of the antibody and the dendrimerbased assay performed better than the commercially available ELISA kit for TNF-α. Compared
to physical adsorption, the dendrimer plate showed significant improvement in detection limit
(0.48 pg/mL vs 8.00 pg/mL) which is 17 times better (Table 3).
Table 3. TNF-α ELISA data obtained from dendrimer plate, and plate prepared
adsorption, TMB detection
TNF-α
Dendrimer TNF-α Conc.
Dendrimer TNF-α
Physical
Plate
Plate
Adsorption
Conc.
(Cytok. mix.)
Conc.
(O.D.) (pg ml-1)
(O.D.)
(O.D.)
(pg ml-1)
(pg ml-1)
300
1.213
300
1.048
500
1.928
240
1.067
240
0.800
250
1.440
80
0.493
80
0.423
125
1.018
26.6
0.270
26.6
0.262
62.5
0.884
8.88
0.192
8.88
0.188
31.2
0.804
2.96
0.151
2.96
0.171
15.6
0.705
0.98
0.137
0.98
0.164
7.5
0.646
0.32
0.143
0.32
0.169
3.75
0.662
0.11
0.141
0.11
0.158
1.87
0.618
0.037
0.136
0.037
0.160
0.94
0.640
0
0.138
0
0.164
0
0
R²
0.996
0.995
0.980

by physical
TNF-α
Kit
(O.D.)
1.287
0.6625
0.3335
0.2045
0.107
0.0655
0.047
0.042
0.035
0.0335
0.0315
0.998

LLDa
0.15
0.17
0.68
0.034
Sensitivity <0.48
<1.14
<8
<1.28
(pg ml-1)
a
The lower limit of detection (LLD) of TNF-α was determined by adding two STD to the mean
OD of three zero standard replicates and calculate the corresponding concentration from the
standard curve.
The sensitivity was obtained from standard curves (Figure 32) as a slope versus
concentration. Compared to kit plate the slope of the dose–response curve for dendrimer plate
(0.0037 versus 0.0027) was steeper, which can be explained by the enhanced binding efficiency
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of the antibodies immobilized on the dendrimer plate. We also performed chemiluminescence
assay (data not shown) for both dendrimer plate and ELISA kit for TNF-α and we found that the
sensitivity was similar to colorimetric assay. This is in an agreement with literature data that the
chemiluminescence method may not give improved sensitivity for every cytokine.114
To assess the overall specificity of the dendrimer-based immunosensors toward TNF-α detection,
the mixture of cytokines was prepared and studied with the dendrimer-modified ELISA plate.
The standard solution containing 300 pg/mL of each of the following: TNF- α, IL-1α, and IL-6
was used to prepare dilutions in the range of 0-250 pg/mL. The selectivity of the dendrimer
modified ELISA plate was examined. No significant difference of OD was observed in
comparison with the result obtained in the presence of only TNF-α (Figure 32).
The precision and reproducibility of the dendrimer plate was determined by calculating
the relative standard deviation (RSD) for three zero standard replicates and coefficient of
variation (CV) for both intra-assay and inter-assay variability, respectively. For immunoassays
such as ELISA, intra- or inter-assay variability should be lower that 8–15 % to be considered
precise enough for its use. In our case the plate had good precision with RSD of 5.4 %. CV for
intra-assay variability was calculated between OD values of triplicates within each run of two
independent assay runs, for each dilution concentration, and it ranged between 0.09 and 13.0 %.
The inter-assay variability was determined by calculating the CV between OD values obtained
from two triplicates of independent assay runs, and it ranged between 2.08 and 13.39 %. This
indicates that the assays on dendrimer modified plates are reproducible.
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3.5 Conclusions
TNF-α is important cytokine in a variety of inflammatory diseases, and is a marker for
chorioaminionitis. The ability to measure accurately and precisely very low concentrations of
TNF-α is very important. In this work the dendrimer based biosensor platform was used for
detection of TNF-α cytokine. Thiol functionalized G4-OH dendrimers were covalently
immobilized onto maleimide-terminated PEG ELISA plate. The dendrimer modified ELISA
plate was reacted to oxidized antibody by coupling the hydrazide groups of dendrimer and
aldehyde groups of oxidized antibody. In this way the capture antibody has favorable orientation
of the antigen binding sites toward the analyte phase. The dendrimer-based capture of TNF-α
shows a detection limit of 0.48 pg/mL for TMB detection, which is significantly better than the
commercial ELISA kit for TNF-α. The dendrimer based diagnostic nanodevice proved to have
improved sensitivity and specificity and can be used for the detection of a wide range of
cytokines and biomarkers.
3.6 Future Work
3.6.1 Detection of Pro-inflammatory Cytokines in Human Samples
An elevated level of pro-inflammatory cytokines such as TNF-α, IL-6, IL-1β, and MMP8 are found in infected intra-amniotic fluid of a pregnant woman. Early detection of these
cytokines is very important to prevent preterm labor. In order to assess the accuracy and
applicability of dendrimer-based assays the cytokine detection can be done using human serum
samples from normal (nonpregnant) and infected women and compared to commercially
available kits.
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CHAPTER

4

“SYNTHESIS

AND

CHARECTERIZATION

OF

DENDRIMER-

PROGESTERON METABOLITE CONJUGATES FOR TRAUMATIC BRAIN INJURY
TREATMENT”
4.1 Abstract
Progesterone, a steroid hormone, and its metabolite allopregnanolone are potential
neuroprotective agents following traumatic brain injury (TBI). The therapeutic use of
progesterone is limited due to its poor solubility and stability. This can be much improved using
dendrimers as delivery vehicles. In this study poly(amidoamine) (PAMAM) dendrimerallopregnanolone nanodevices are designed for TBI treatment. Two conjugates have been
synthesized,

dendrimer-allopregnanolone

and

dendrimer-allopregnanolone

isomer,

and

characterized by proton NMR, HPLC and MALDI-TOF mass spectroscopy. Release study of
dendrimer-allopregnanolone isomer showed no drug release in PBS buffers with varios pH (7.4,
4.6, and 1.4) due to short spacer between the drug and dendrimer. Based on this, dendrimerallopregnanolone conjugate was prepared by putting longer spacer between drug and dendrimer.
Allopregannaolone released from the conjugate in PBS buffer pH 2.1 in a sustained manner. The
realase was evaluated by reverse phase HPLC (RP-HPLC) analysis, and 90% of drug payload
was released within 9 days. In future study, the pharmacological activity of dendrimerallopregnanolone conjugate, by measuring the inhibition of prostaglandin secretion, will be
evaluated in vitro using A 549 lung epithelial cells.
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4.2 Introduction
Traumatic brain injury (TBI) occurs when an external force traumatically injures the
brain. It is a significant public health problem that affects nearly 1.5 million Americans each year
resulting in more than 50,000 deaths.115 Initially TBI causes ionic imbalances, oxidative damage,
microglial activation, immune cell invasion, and cytokine release.116,117 This can result in
cerebral edema, inflammation, tissue necrosis, apoptosis, etc. No matter which factors initiate the
injury cascade, the inhibition of inflammation may reduce cell death, gliosis, and edema.118,119
Currently there are no treatments that improve clinical outcome measures. The research findings
have shown that the progesterone and its reduced metabolite allopregnanolone, (5α -pregnane3α-ol, 20-one or 5α -tetrahydroprogesterone) may be promising therapeutics for TBI treatment
(Figure 33).120,121 Progesterone is a steroid hormone involved in female menstrual cycle,
pregnancy, and embryogenesis of humans and other species. It belongs to the group of
neurosteroids. Progesterone is produced by the adrenal glands, the corpus luteum, as well by
neurons and glial cells within the central and peripheral nervous system.122 Progesterone showed
several different modes of neuroprotection following TBI, including the reduction of cerebral
edema,123 the reduction of lipid peroxidation and oxidative stress,124

anti-inflammatory

effects,118 reduction of cellular apoptosis,125 inhibition of excitotoxicity,126 and helps myelin
repairement.122,127 Progesterone has also neuroactive properties that can modulate neuronal
excitability and seizure activity.128,129 There are two mechanisms engaged in neuroprotective
effects of progestrone: binding to progesterone receptors (PRs) and its metabolite to GABA-A
receptor modulating neurosteroids.131,133 Progesterone binding to cytoplasmic PRs of target cells
leads to the formation of the hormone-nuclear receptor complexes to translocate to the cell
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nucleus where they activate or stop the transcription of downstream gene networks, therefore
affect the physiological response of progesterone-responsive target cells.131 However, numerous
studies have showed that the antiseizure effects of progesterone do not directly result from
interactions with classical PR. These studies support the idea that 5α-reduced metabolites of
progesterone,

predominantly

allopregnanolone,

are

responsible

for

the

seizure

protection.128,130,131 Allopregnanolone is synthesized from progesterone via two sequential A-ring
reductions both in peripheral tissues and in the brain. It binds to a steroid-binding site on the
GABA-type A (GABAA) receptor, and potentiates its function leading antiseizures effects. It is
assumed that GABA-A receptors are pentameric with five protein subunits that form the chloride
ion channel pore. GABA-A receptors are mostly composed of α, β and γ or δ subunits.
Allopregnanolone has unique binding site on GABA-A receptors. Even though that binding of
allopregnanolone to PRs is poor, it could indirectly activate PRs by re-conversion to
dihydroprogesterone that is a moderately potent PR agonist. Progesterone and neurosteroids also
affect GABA-A receptor expression. Therefore, there may be an interaction between genomic
and non-genomic actions of progesterone that are involved in seizure protection.

131

Allopregnanolone plays a variety of neurprotective roles during gestation. It also showed
improved seizure control in women suffering from catamenial epilepsy.128,131

Figure 33. Chemical structures of progesterone and its metabolite allopregnanolone.
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Due to their exceptional properties dendrimers are emerging as potential nanoscale
delivery vehicles. They are nearly monodisperse, tree-like polymers with a large density of
tailorable, functional end groups. Dendrimers have ability of conjugation, complexation, and
encapsulation of multifunctional moieties.2 In this study hydroxyl terminated PAMAM
dendrimers are being explored as drug delivery vehicles for TBI treatment. Two conjugate
nanodevices were synthesized: PAMAM dendrimer-allopregnanolone 3β,5β-isomer and
PAMAM dendrime-allopregnanolone. The isomer of allopregnanolone has been modified to its
succinate by reacting to succinic anhydride and conjugated directly to poly(amidoamine)
dendrimer (PAMAM) through an ester bond. However the allopregnanolone was modified to
allopregnanolone succinate and conjugated to bifuctional dendrimer through and amide bond.
Bifuctional dendrimer was prepared by reaction of hydroxyl-terminated poly(amidoamine)
dendrimer (G4-OH) to a protected amine linker followed by deprotection. The role of the linker
on the dendrimer is to help the drug release in a resonable manner. Coupling the drugs to
dendrimer the solubility and stability limitations of progesterone, as well as multistep enzymatic
synthesis of allopregnanolone will be avoided. This approach will allow for dose reduction
leading to fewer side effects and based on targeting ability of dendrimers the efficacy of the drug
is expecting to be increased.
4.3 Materials and Methods
4.3.1 Materials
Hydroxyl terminated G4-PAMAM dendrimer (G4-OH) was purchased from Dendritech®,
Inc. (Midland, MI). DMSO-d6 and CDCl3 was purchased from Cambridge Isotope Laboratories.
Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), K-Selectride
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1M in THF, 5-(tert-butoxycarbonyl-amino)butyric acid, sodium borohydride, succinic anhydride,
pyridine, diisoprophylethylamine (DIEA), and MALDI-MS reference standards were purchased
from Sigma-Aldrich. Triethylamine (TEA) and ethylene diamine (EDA) were purchased from
Thermo Scientific. Palladium, 5% on calcium carbonate, was obtained from Alfa Aesar, MA,
USA. Sodium hydroxide was obtained from Fisher Scientific. Trifluoroacetic acid (TFA) was
purchased from EMD. Anhydrous DMSO, dichloromethane (DCM), and tetrahydrofuran (THF)
were purchased from Acros Organics, USA. All other solvents and chemicals used were
purchased from Fisher Scientific. Regenerated cellulose (RC) dialysis membrane with molecular
weight cut-off of 1000 Da was obtained from Spectrum Laboratories.
4.3.2 Characterization
NMR spectra were recorded on a Varian INOVA 400 spectrometer using commercially
available deuterated solvents. Proton chemical shifts are reported in ppm (δ) and
tetramethylsilane (TMS) used for internal standard. ESI mass spectra were recorded on Waters
Micromass ZQ spectrometer. Matrix-assisted laser desorption ionization-time of flight (MALDITOF) mass spectra were recorded on a Bruker Ultraflex system equipped with a pulsed nitrogen
laser (337 nm), operating in positive ion reflector mode, using 19 kV acceleration voltage and a
matrix of 2,5-dihydroxybenzoic acid. Cytochrome C (MW 12,361 g/mol), and Apomyoglobin
(MW 16,952 g/mol) were used as external standards. A dendrimer solution was prepared by
dissolving 2 mg of dendrimer in 1 mL of DMSO. The matrix solution was prepared by
dissolving 20 mg of matrix in 1 mL of the 1:1 mixture of deionized water and acetonitrile (0.1%
TFA). Analytical samples were prepared by mixing 10 µL of dendrimer solution with 100 µL of
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matrix solution, followed by deposition of 1 µL of sample mixture onto a 384-well aluminum
plate. This mixture was allowed to air dry at room temperature.
4.3.3 High performance liquid chromatography (HPLC)
HPLC characterization was carried out using Waters HPLC instrument equipped with
dual pumps, an auto-sampler and dual UV detector interfaced to Breeze software. The HPLC
chromatogram was monitored at 210 and 205 nm simultaneously using the dual UV absorbance
detector. H2O:ACN (0.14 % TFA) was used as mobile phase. Both phases were freshly prepared,
filtered, and degassed prior to use. Symmetry300 C18 reverse-phase column (5 µm particle size,
25 cm × 4.6 mm length × I.D.) equipped with a Supelguard Cartridges (5 µm particle size, 2.0
cm ×3.9 mm length × I.D.) was used for characterization of the conjugates. HPLC analysis was
done using 90:10 to 10:90 (H2O:ACN) gradient flow in 30 minutes with flow rate of 1 mL/min.
4.3.4 Release Study Protocol
The release studies were performed in 0.1M PBS buffer solution pH 7.4, 0.1 M citrate
buffer pH 4.6, and 0.1 M hydrochloric acid buffer pH 2.1. The conjugates were added into 3 mL
preheated buffer solutions in triplicates. All the release solutions containing 3.0 mg/mL
dendrimer drug conjugates were stirred continuously and maintained at 37ºC. At appropriate
time intervals samples were withdrawn and immediately analyzed by HPLC to determine the
drug concentrations.
4.3.5 Synthesis
4.3.5.1 5β
β Reduction Product of Progesterone
The reaction scheme is outlined in Figure 34. Progesteron (1.00 g, 3.18 mmole) was
dissolved in 66 mL absolute ethanol in a round bottom flask, and KOH (0.180 g) and 5%
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Pd/CaCO3 (0.090 g) were added. The flask was evacuated, flushed with hydrogen and the
reaction mixture stirred for 1 hour. The ethanol was removed and the residue was redissolved in
ether and washed with water. The water layer was extracted with ether twice. The aqueous layer
was then acidified to pH<3 with 1M HCl and extracted with ether. The organic layers were
combined, dried, filtered, and concentrated to give crude 5β reduction product. The pure 5β
reduction product was isolated by flash column chromatography on silica gel using ethyl
acetate/hexanes (1:5) as mobile phase (0.60 g, yield 60%); Rf = 0.16 (1:5 ethylacetate /hexanes),
and it was characterized by proton NMR. 1H NMR (CDCl3) δ 2.66 (t, 1H, J = 15 Hz), 2.53 (t,
1H, J = 9.0 Hz), 2.34 (dt, 1H, J 14.4, 5.4 Hz), 2.21-1.09 (m, 20H), 2.12 (s, 3H), 1.02 (s, 3H), 0.64
(s, 3H). ESI MS (m/z): calcd for C21H32NO2 [M+H]+ 317.2481, found 317.2471.

Figure 34. Synthesis of 3β,5β allopregnanolone isomer from progesterone.
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4.3.5.2 Allopregnanolone Isomer
The reaction pathway is shown in Figure 34. The pure 5β reduction product (0.849 g,
2.68 mmole) dissolved in dry THF (5 mL) under nitrogen atmosphere and cooled down to 78°C.
To this 3.22 mL of K-Selectride was added. The reaction mixture was stirred for 1.5 hours at
78°C, and 1 hour at 0°C. Then 7 mL of 10% NaOH and 5 mL of 30% H2O2 added followed by
overnight stirring at room temperature. The product was extracted by ethylacetate three times.
Organic layers combined and washed with water two times, sodium bisulfate two times and brine
two times, dried over NaSO4 and evaporated under reduced pressure. The pure product, of 3β,
5β-tetrahydroprogesterone was isolated by flash column chromatography on silica gel using
ethylacetate/hexanes (1:3) as mobile phase (0.765 g, yield 90%); Rf = 0.28 (1:3 ethyl acetate
/hexanes), and it was characterized by proton NMR. 1H NMR (CDCl3) δ 4.091 (t, 1H), 2.499 (t,
1H), 2.200 - 1.000 (m, 23H), 2.081 (s, 3H), 0.930 (s, 3H), 0.568 (s, 3H). ESI MS (m/z): calcd for
C21H35O2 [M+H]+ 319.2637, found 319.2630..
4.3.5.3 Allopregnanolone Isomer Succinate (3β
β , 5β
β-tetrahydroprogesterone Succinate)
The reaction scheme is shown in Figure 35. Succinic anhydride (383.95 mg, 3.8364
mmole) and DMAP (78.08 mg, 0.6394 mmole) added to a solution of 3α, 5βtetrahydroprogesterone (203.00 mg, 0.6394 mmole) in pyridine. The reaction mixture stirred
under N2 and 45°C and monitored by TLC plate until its completion. After 24 hours the reaction
stopped, and the solvent was evaporated. The crude product was redissolved in dichloromethane
and washed with water. The water layer was washed three times with dichloromethane. Organic
layers combined and washed with water and brine, dried over NaSO4 and evaporated under
reduced pressure. The pure product was isolated by flash column chromatography on silica gel
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using ethylacetate/hexanes (2:3) as mobile phase (214 mg, yield 80%); Rf = 0.35 (2:3 ethyl
acetate /hexanes), and it was characterized by proton NMR. 1H NMR (CDCl3) δ 5.092 (t, 1H),
2.556-2.700 (m, 4H linker), 2.087 (s, 3H), 2.000-1.000(m, 23H), 0.934 (s, 3H), 0.576 (s, 3H).
ESI MS (m/z): calcd for C21H37O5 [M-H]+ 417.2641, found 417.2652.

Figure 35. Synthesis of G4-OH PAMAM – allopregananolone isomer nanodevice.

4.3.5.4 Allopregnanolone Succinate (3α
α, 5α
α-tetrahydroprogesterone Succinate)
Allopregnanolone succinate was prepared in the same way as allopregananolone isomer
succinate. Pure product was isolated by flash column chromatography and characterized by
proton NMR . 1H NMR (CDCl3) δ 5.027 (t, 1H), 2.600-2.700 (m, 4H linker), 2.505 (t, 1H), 2.124
(m, 1H), 2.095 (s, 3H), 1.970 (m,1H) 1.750-1.080(m, 19H), 0.926 (m, 1H), 0.766 (m, 1H) 0.766
(s, 3H), 0.582 (s, 3H).
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4.3.5.5 G4-OH PAMAM – Allopregnanolone Isomer Nanodevice
The reaction scheme for the preparation of the conjugate is outlined in Figure 35. The
allopregnanolone isomer-succinate (52.0 mg, 0.1242 mmole) dissolved in DMF (1 mL) and
cooled down to 0°C using ice water bath. To this PyBOP (96.0 mg, 0.1863 mmole) dissolved in
DMF (1 mL) and DIEA (32.54 µL, 0.1863 mmole) added under nitrogen atmosphere. Ice water
bath removed and the mixture stirred for 1 hour at room temperature. Then PAMAM G4-OH
(113.0 mg, 0.0079 mmole) dissolved in DMF (2 mL) added to the reaction mixture. The reaction
stirred for 48 hours at room temperature. The resulting solution dialyzed extensively with DMF
(dialysis membrane of molecular weight cutoff = 1000 Da) for 24 h. The obtained reaction
mixture lyophilized yielding G4-OH PAMAM-allopregnanolone isomer conjugate with ester
linker. The conjugate was characterized by proton NMR. 1H NMR (DMSO-d6, 400 MHz): δ
(ppm) 8.048 (bs, CO-NH, linker), 7.939 (bs, CO-NH, G4-OH), 7.783 (bs, CO-NH, G4-OH),
4.298 (t, 1 H, Allo-iso), 4.715 (bs, OH, G4-OH), 3.989 (m, CH2OCO, G4-OH), 3.37-2.16 (m,
984 H aliphatic protons, G4-OH; 4 H CH2, linker; 28 H, Allo-iso), 2.034 (s, 3 H, Allo-iso-CH3)
2.000-1.000 (m, 23H, Allo-iso), 0.895 (s, 3H, Allo-iso-CH3), 0.482 (s, 3 H, Allo-CH3).
4.3.5.6 G4-OH PAMAM – Allopregnanolone Nanodevice
The reaction scheme is shown in Figure 36. Allopregnanolone-succinate (22.0 mg,
0.0526 mmole) dissolved in DMF (1 mL) and cooled down to 0°C using ice water bath. To this
PyBOP (41.0 mg, 0.0788 mmole) dissolved in DMF (1 mL) and DIEA (15.0 µL, 0.0788 mmole)
added under nitrogen atmosphere. Ice water bath removed and the mixture stirred for 1 hour at
room temperature. Then bifuctional PAMAM dendrimer (100.0 mg, 0.0066 mmole) dissolved in
DMF (2 mL) added to the reaction mixture. The reaction stirred for 48 hours at room
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temperature. The resulting solution dialyzed extensively with DMF (dialysis membrane of
molecular weight cutoff = 1000 Da) for 24 h. The obtained reaction mixture lyophilized yielding
G4-OH PAMAM-link-allopregnanolone conjugate. The conjugate was characterized by proton
NMR. 1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.042 (bs, CO-NH, linker), 7.931 (bs, CO-NH,
G4-OH), 7.770 (bs, CO-NH, G4-OH), 4.853 (t, 1 H, All), 4.705 (bs, OH, G4-OH), 3.977 (m,
CH2OCO, G4-OH), 3.40-1.90 (m, 984 H aliphatic protons, G4-OH; 4 H CH2, linker; 6 H, Allo),
1.750-1.080 (m, 19 H, Allo), 0.833 (m, 1 H, Allo), 0.727 (s, 3H, Allo-CH3), 0.482 (s, 3 H, AlloCH3).
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4.4 Results
4.4.1 Synthesis of Nanodevices
G4-OH-Allopregnanolone Isomer Nanodevice. The nanodevice was prepared by coupling
reaction of G4-OH dendrimer with allopregnanolone isomer succinate. Since allopregnanolone is
a quite expensive compound (Sigma – Aldrich sells 10 mg for $159.50), for preliminary studies
the isomer of allopregnanolone was synthesized from progesterone following already published
procedures (Figure 34).134,135 Hydrogenation of progesterone in the presence of hydroxides is
known to provide 5β reduction product. Treatment of 5β reduction product with K-Selectride in
dry THF leads to selective reduction of the C-3 carbonyl in the presence of the C-20 ketone
giving allopregnanolone isomer (or 3β, 5β-tetrahydroprogesterone) product. Then reaction of
allopregnanolone isomer with succinic anhydride produces a succinate having a carboxylic group
required for the coupling reaction to dendrimer. All three compounds are charectirized by mass,
proton NMR, and HPLC. The HPLC chromatograms showed that the retention times for
allopregananolone isomer, 5β reduction product of progesterone, and allopregnanolone isomer
succinate were 25.50, 26.00 and 26.23 min respectively (Figure 37). The allopregnanolone
isomer succinate was conjugated to dendrimer using an ester link for ‘slow drug release’. The
specific steps of the synthesis of allopregnanolone isomer-dendrimer nanodevices, is shown in
Figure 35. Brifely, the nanodevices was obtained by coupling hydroxyl terminated generation 4
PAMAM dendrimer with allopregnanolone isomer succinate using PyBOP (as a coupling agent)
in the presence of catalytic amount of DIEA in DMF. The resulting conjugate was purified by
dialysis in DMF, lyophilized, and charectirized using NMR, MALDI-TOF MS, and HPLC.
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Figure 37. HPLC chromatograms of G4-OH (red), G4-OH-allopregnanolone isomer conjugate
(blue), allopregananolone isomer (light blue), 5β reduction product of progesterone (green), and
allopregnanolone isomer succinate (black)
The HPLC spectra showed that the conjugate G4-OH-allopregnanolone isomer gave very
distinct broad peak at 18.9 min compared to G4-OH dendrimer that gave a peak at 7.2 min
(Figure 37). The proton NMR of G4-OH-allopregnanolone isomer conjugate is shown in Figure
38. Comparison of the integration of amide peaks of dendrimer and methyl groups of
allopregnanolone revealed that three molecules of allopregnanolone isomer were attached to the
surface of the dendrimer.
MALDI-TOF MS spectra of G4-OH-allopregnanolone isomer conjugate is shown in
Figure 39. The obtained molecular weight of G4-OH-allopregnanolone isomer (15,686.4)
compared with G4-OH (13,949.5) suggests that a payload of approximately three to four
molecules of allopregnanolone isomer was achieved. This represents a drug payload in the
conjugate of ~8% by weight. The conjugate was soluble in PBS buffer pH 7.4, compared to the
free allopregnanolone isomer which is not.
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Figure 38. Proton NMR spectrum of dendrimer-allopregnanolone isomer conjugate in DMSOd6 .

Figure 39. MALDI-TOF MS spectra of G4-OH PAMAM-allopregananolone isomer conjugate.
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G4-OH-Link-Allopregnanolone Nanodevice. For the synthesis of this nanodevice a
bifuctional dendrimer was used to improve the drug release from dendrimer by putting an
additional spacer between drug and dendrimer, Figure 36. The bifunctional dendrimer was
prepared by reacting 4-Boc-amino-butyric acid, as a linker to provide protected NH2 groups, and
G4-OH hydroxyl terminated dendrimer followed by deprotection of Boc protected amine groups.
Based on proton NMR and and MALDI-TOF mass (not shown here) there are approximately 5-6
amine groups added. Then bifuctional dendrimer was reacting to allopregnanolone succinate to
obtain G4-OH-link-allopregnanonolone conjugate. The conjugate was thoroughly characterized
by proton NMR (Figure 40), HPLC (Figure 41), and MALDI-TOF mass (Figure 42). Based on
proton NMR and MALDI-TOF mass analyses five molecules of allopregnanolone were attached
to dendrimer giving the drug payload ~10% by weight.

Figure 40. Proton NMR spectrum of dendrimer-allopregnanolone conjugate in DMSO-d6.
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Figure 41. HPLC chromatograms of G4-OH, bifuctional
allopregnanolone conjugate, and allopregnanolone at 205 nm.

dendrimer,

G4-OH-link-

Figure 42. MALDI-TOF MS spectra of G4-OH PAMAM-allopregananolone conjugate.
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4.4.2 Release Studies
In vitro drug release rate from dendrimer-drug nanodevices were carried out at various
pH values at 37°C and analyzed by HPLC at 205 nm. The drug release rate of G4-OHallopregananolone isomer nanodevice was studied at pH 2.1, 4.6, and 7.4 and HPLC analysis
showed no drug release from conjugate. The stability of ester linkages of the G4-OHallopregananolone isomer nanodevice could be attributed to the size and chemical structure of
the spacer between the drug and dendrimer as well as steric effect caused by dendrimer structure.
To increase the drug release kinetics, G4-OH-link-allopregnanolone nanodevice was designed.
The design consisted of the conjugation of allopregnanolone having succinic acid linker with
bifuctional dendrimer (G4-OH dendrimer having several linkers with end amine groups) giving
G4-OH-link-allopregnanolone nanodevice. In this case the spacer was longer and had peptide
link and resulted in successful drug release from dendrimer. The drug release rate of this
nanodevice was studied in hydrochloric acid buffer pH 2.1 and HPLC analysis showed that the
nanodevice was susceptible to hydrolysis and about 90% of the drug was released within 9 days
(Figure 43). HPLC chromathogram cleary showed the appereance of the drug peak and peak of
the bifuctional dendrimer with the time (not shown here). This indicates that the hydrolytic
cleavage of ester bond on the dendrimer’s side is quite stable. The release rate of
allopregnanolone appears to be following first order reaction kinetics. The logarithmic equation
was fitted to the release profile as shown in Figure 43. The equation fits fairly well and this
indicates that the release of the drug from nanodevice depends on the concentration of the drug.
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Figure 43. Drug release profile of G4-OH-link-allopregnanolone nanodevice at pH 2.1.
4.5 Discussion
TBI is a significant public health problem throughout the world. It can cause cerebral
edema, inflammation, tissue necrosis, programmed cell death, etc. The research findings have
shown that the progesterone may be a promising therapeutic drug for the treatment of TBI.
Progesterone belongs to the group of neurosteroids. It has a variety of neurprotective roles during
gestation, and it has also been linked to several different modes of neuroprotection following
TBI, including the attenuation of cerebral edema, the reduction of lipid peroxidation and
oxidative stress, anti-inflammatory effects, reduction of cellular apoptosis, inhibition of
excitotoxicity, and assisting in the repair of myelin. However, the poor aqueous solubility of
progesterone limits its potential use as a therapeutic. It is known that the protective effects of
progesterone in the brain arise largely from its conversion to 5α-reduced metabolites such as
allopregnanolone (5α -pregnane-3α ol, 20-one or 5α -tetrahydroprogesterone). Allopregnanolone
binds to a steroid-binding site on the GABAA receptor complex, and by increasing chloride flux
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thereby increase GABAergic receptor activity and decrease the excitability of the central nervous
system.
In this study allopregnanolone and allopregnanolone isomer were conjugated to
generation 4 hydroxyl PAMAM dendrimer as a drug carrier with a longer and shorter spacer
respectively. Since release study of G4-OH-allopregnanolone isomer at pH 7.4, 4.6, and 2.1
showed no drug release from conjugate, allopregnanolone was reacted first to succinic anhydride
to obtaine an acid group required for conjugation raction with the dendrimer and then conjugated
to bifuctional dendrimer that is G4-OH dendrimer having several linker moieties terminated with
amine groups. The spacer between drug and dendrimer had a peptide link and because it was
longer moved drug molecules a little bit further from dendrimer reducing the steric effect and
resulted in effective drug release in acidic conditions. Around 90% of allopregnanolone was
successfully released in 9 days from the dendrimer-drug nanodevice at 2.1 pH. Future study will
involve in vitro determination of pharmacological activity of dendrimer-allopregnanolone
nanodevices, by measuring the inhibition of prostaglandin secretion in LPS pretreated A 549
lung epithelial cells.
4.6 Future Work
4.6.1 Pharmacological Activity of Dendrimer-Allopregnanolone Nanodevice
Prostaglandins (PGs) play a key role in the generation of the inflammatory response.
Their concentration is elevated in inflamed tissue and can lead to acute inflammation. To
evaluate the therapeutic potential of dendrimer-allopregnanolone nanodevices, in inhibiting the
prostaglandin synthesis, an in vitro study can be demonstrated using A549 human lung epithelial
carcinoma cell lines. The pretreated cells with lipopolysaccharide induce prostaglandin synthesis.
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The inhibition of prostaglandin synthesis by dendrimer-allopregnanolone nanodevices would be
the measure of anti-inflammatory activity of the nanodevices.
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APPENDIX
Selected 1H ans ESI MS Spectra
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Proton NMR of 5β Reduction Product

ESI MS of of 5β Reduction Product,
(m/z): calc. for C21H32O2 [M+H]+ 317.2481, found 317.2471
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Proton NMR of Allopregnanolone Isomer.

ESI MS Allopregnanolone Isomer
(m/z): calc. for C21H35O2 [M+H]+ 319.2637, found 319.2630
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Proton NMR of Allopregnanolone Isomer Succinate.

ESI MS of Allopregnanolone Isomer Succinate
(m/z): calc. for C21H37O5 [M-H]+ 417.2641, found 417.2652
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Proton NMR of Allopregnanolone Succinate
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ABSTRACT
PAMAM DENDRIMER-BASED THERAPEUTIC AND DIAGNOSTIC NANODEVICES
by
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Degree: Doctor of Philosophy
Dendrimers are ideal materials to be used in the emerging field of nanomedicine. Their
nanoscale size and high density of functional groups on their peripheries allow them to be used
for various biomedical applications. This work exploits dendrimers as drug delivery vehicles and
a versatile platform for capturing biomarkers with improved sensitivity and specificity. Hydroxyl
terminated poly(amidoamine) dendrimer (PAMAM-OH) was modified with a linker having
amine group at the end and conjugated to two drugs, erythromycin (EM) and allopregnanonolne,
respectively and evaluated in vitro. Both drugs were provided with a linker having carboxylic
group required for conjugation reaction with dendrimer. The release rate of the drugs from the
conjugates in PBS buffers at pH 7.4 for EM and pH 2.1 for allopregnanolone were evaluated by
reverse phase HPLC (RP-HPLC) analysis. EM released quite fast, about 90% of the drug was
released within 10 hours and completed within 20 hours, while allopregnanolone released in
slower manner, about 90% of the drug was released within 9 days. Dendrimer-EM conjugate was
not cytotoxic and was significantly efficacious in inhibiting the nitrite production compared to
free drug. The inhibition of bacterial growth by dendrimer-EM conjugate was comparable to free
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EM. Combined with the intinsinic properties of dendrimers, these nanodevices could lead to
improved in vivo efficacy. PAMAM-OH was successfully used for the development of a solid
phase bio-sensing platform. The ELISA plate was modified first with polyethylene-glycol (PEG)
and then PAMAM-OH was immobilized. A capture antibody was oxidized and covalently
attached to dendrimer-modified ELISA plate which gives antibody favorable orientation for the
antigen binding sites toward the analyte. The dendrimer modified plate showed enhanced
sensitivity and the detection limit for TNF-α was found to be 0.48 pg/mL, which is significantly
better than the commercially available ELISA kit. The selectivity of the dendrimer-modified
ELISA plate was examined by studying TNF-α in a mixture of cytokines which gave similar
results. Dendrimer-modified ELISA plate provides a greater opportunity for the detection of a
wide range of cytokines and biomarkers.
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